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Pharmaceuticals in the aquatic environment is an emerging issue and 
the risks they pose are mostly unknown. They are used in large amounts 
throughout the world and can enter the environment, as the active metabolite or 
unmetabolised, through excretion by people and improper disposal. As these 
drugs are designed to have specific biological effects in a specific organism (as 
well as sometimes having other non-specific side effects), their potential to 
cause effects within the environment is great. Clofibric acid (the major 
metabolite of the lipid lowering drug, Clofibrate) is non-biodegradable, highly 
motile, very persistent and frequently detected at µg/I levels in the environment. 
I studied possible effects of clofibric acid in fish, using different 
experimental approaches and endpoints. The studies involve two different 
species, and for one of these species, fish at different stages of development. 
The chapters within this thesis have presented the first evidence (albeit 
preliminary) of clofibric acid having effects on both adult and embryo fish. 
When fathead minnow embryos were exposed to clofibric acid, the 
effects seen included changes in the eggshell, time to hatch, hatchability, 
mortality and viability. Adult fathead minnow were similarly exposed and 
significant effects on specific parameters were also observed. These included 
effects on lipid metabolism, steroidogenesis and spermatogenesis - thought to 
be via cholesterol transport - as well as significant effects on the expression of 
several genes involved in lipid metabolism and detoxification. Exposure of 
juvenile (sexually undifferentiated) bream also found significant differences in 
some endpoints. Other results suggested, less pronounced effects of clofibric 
acid on some other parameters. 
The results from this research show that there are effects of clofibric acid 
in pathways which were not only unexpected in fish (for example, 
steroidogenesis, spermatogenesis and gene expression), but also at 
concentrations below those previously shown to have any biological effects on 
fish. These effects indicate that clofibric acid may potentially have an impact on 
fish fecundity, and even more worryingly, on human health for those people 
prescribed it. 
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STW Sewage treatment works 
TGRL Triglyceride rich lipoproteins 
VHDL Very High Density Lipoprotein 
VLDL Very Low Density Lipoprotein 
VTG Vitellogenin 
Zrp/ZP3 Zona radiata protein/3 
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Chapter 1: General Introduction 
Anthropogenic contaminants are present worldwide in the aquatic 
environment. These pollutants range from those of historic concern, like 
organochlorine pesticides, polychlorinated biphenyls, polychlorinated dioxins 
and furans and polycyclic aromatic hydrocarbons, to emerging contaminants 
such as pharmaceuticals and personal care products (Petty, et al, 2004). 
During the last three decades, assessments of the impact of chemical pollution 
has focused almost exclusively on 'priority' pollutants, such as endocrine 
disrupting, carcinogenic and toxic chemicals. These are, however, only a small 
piece of a larger puzzle (Daughton, and Ternes, 1999). 
Pharmaceuticals represent a large group of chemicals that have until 
recently received little attention; they are used in large amounts throughout the 
world and their usage is increasing exponentially. In the UK alone, for example, 
there are currently 3000 active compounds used as constituents of medicinal 
products, which comprise a wide range of chemical structures (Ternes, 2001, 
Ayscought et al, 2000). They enter the environment, some excreted 
unmetabolised, some as the active metabolite (after escaping degradation in 
waste water treatment), and some through improper disposal of industrial 
waste. 
In more recent years, a number of research groups have reported the 
presence of these pharmaceuticals in the aquatic environment (Snyder et al, 
2003). They include: steroids, anti-inflammatory, anti-cancer, lipid regulators, 
anti-epileptic, antibiotics and painkillers. Clofibric acid, a lipid lowering drug, was 
one of the first drug residues to be found in the environment, back in 1976, 
when US researchers analysed domestic sewage (ENDS, 2000). Little is 
currently known about the environmental impact of these drugs and there is 
currently no regulation or monitoring of their entry into the environment 
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(although as part of registration for new drugs, companies are now required to 
conduct environmental risk assessments (Ayscought, et al, 2000)). As these 
drugs are developed to have a biological effect, their potential to cause effects 
within the environment is great. 
1.1 General pharmaceutical use in the UK 
In the UK, records of drug use are kept by the Department of Health (for 
prescription drugs) and the Proprietary Association of Great Britain (for over- 
the-counter drugs), both of which only keep a record of drug use in terms of the 
number of prescription items issued. This type of data is therefore not very 
useful when trying to determine the amount of drugs (or their metabolites) 
present in the aquatic environment. It does, however, give indications of the 
groups of drugs that have the potential to enter the environment. The data in 
Table 1.1 below are likely to be an underestimation of total drug use, because 
they do not include over-the-counter drugs or illegally acquired drugs. 
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Compound name Therapeutic use Amount used 
er ear k 
Paracetamol Analgesic 390,954.26 
Metformin hydrochloride Anti-hyperglycaemic 205,795.00 
Ibuprofen Analgesic 162,209.06 
Amo c llin Antibiotic 71,466.83 
Sodium valporate Anti-epileptic 47,479.65 
Sulphasalazine Antirheumatic 46,430.43 
Mesalazine (systemic) Treatment of ulcerative colitis 40,421.7 
Carbamazepine Anti-epileptic 40,348.75 
Ferrous sulphate Iron supplement 37,538.52 
Rantidine hydrochloride Anti-ulcer drug 36,319.24 
Cimetidine H2 receptor antagonist 35,654.20 
Naproxen Anti-inflammatory 35,065.98 
Atenolol -Blocker 28,976.55 
O retrac cline Antibiotic 27,195.11 
Erythromycin Antibiotic 26,483.78 
Diclofenac sodium Anti-inflammatory and analgesic 26,120.53 
Flucloxacilin sodium Antibiotic 23,381.47 
Pheno meth I enicillin Antibiotic 22,227.59 
Allopurinol Anti out drug 22,095.64 
Diltiazem hydrochloride Calcium antagonist 21,791.50 
Gliclazide Antih er I caemic 18,783.11 
Aspirin Analgesic 18,105.89 
Quinine sulphate Muscle relaxant 16,731.26 
Mebeverine hydrochloride Antispasmodic 15,497.35 
Mefenamic acid Anti-inflammato 14,522.77 
Table 1.1: The 25 most used pharmaceuticals by weight in England in 
2000. Taken from Jones et al, (2002). 
1.2 Pharmaceuticals present in environment 
Pharmaceuticals have probably been around in the environment for as 
long as they have been in use. It was not until the early nineties that the 
analytical techniques needed to accurately detect these compounds in complex 
environmental samples such as sewage or river waters were developed. As 
methods improve (sensitivity of methods increases), lower and lower levels are 
detectable. Consequently, more and more of these compounds have been 
detected in the environment. Currently more than 80 have been detected. 
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The concentrations of drugs that have been found routinely in surface 
waters and sewage effluent vary, but are in trace amounts (at the ng/l level, or 
at the most the low pg/I level). Some studies (associated with older landfills 
over vulnerable aquifers) have also found them to be present in ground water 
and in drinking water (Heberer and Stan, 1996; Fielding et al, 1981). Currently, 
no quantitative data have been reported on the presence of pharmaceuticals in 
sewage sludge (probably due to analytical difficulties), but this is a highly likely 
route for the pharmaceutical substances to enter the terrestrial environment. 
1.3 Routes of entry 
The routes of entry of pharmaceuticals into the environment are 
summarised in Figure 1.1. The main routes for human pharmaceuticals 
entering the environment are expected to be through use by patients in 
hospitals, medical centres, or in the community, or through the disposal of 
unused or out-of-date drugs (via toilet or drain), landfills (domestic rubbish) or 
as licensed waste (Ayscought of al, 2000). Another route becoming 
increasingly important is aquaculture. Over-feeding, loss of appetite (by 
diseased fish) and poor absorption leads to the introduction of drugs via the 
feed, which are consequently discharged directly into the water (up to 70% of 
the drugs administered; Diaz-Cruz et al, 2003). 
In humans, most pharmaceuticals, once administered, are degraded in 
the body, and may even become inactivated. Others, particularly those 
excreted renally or those not absorbed fully by the body, can leave in their 
active form. Drugs can be excreted as either the parent compound, water- 
soluble conjugates or as metabolites. These then enter the aquatic 
environment via the sewage system, where they can have their unknown 
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effects. The effects and side effects specified in humans may not automatically 
correlate to the effects that may occur in organisms exposed to the drugs in the 
environment. 
Human Medicine Veterinary medicine 
Aquaculture Livestock Poultry 
Excretion Disposal Excretion 
ewage Domestic waste Manure 
nvArflnw 
Treatment plant] Landfill SoiVA ricultural soil 
Run 
Sludge Surface waters Ground water Food chain 
Drinking water 
Figure 1.1: Principal routes into the environment for human and 
veterinary drugs (adapted from Diaz-Cruz of al, 2003). 
1.4 Drugs found to be present in the environment 
1.4.1 Introduction 
Low levels of reproductive hormones, steroids, antibiotics and numerous 
prescription and non-prescription drugs as well as their metabolites have been 
detected in European and US waters (Erickson, 2002). Only a few have been 
shown to be completely degraded during the sewage treatment (ENDS, 2000; 
Daughton and Ternes, 1999) and generally most are lipophilic; these properties 
lead to the potential for bioaccumulation and persistence in the environment 
(Christensen, 1998). As little is known about their mode of action or effect on 
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non-target organisms, it is difficult to predict what health effects they may have 
individually or collectively on aquatic organisms that are exposed to them. Even 
apparently slight, non-significant influences on single parameters, which would 
probably not result in any acutely discernable effect, might ultimately affect a 
whole population by their negative consequences on fitness, disturbance of 
hormonal homeostasis (e. g. endocrine disruption), immunological status, signal 
transduction or gene regulation (Seiler, 2002). Daughton and Ternes (1999) 
also indicate that some drug residues in the environment could have subtle 
behavioural effects that could be undetectable or overlooked, but may 
nonetheless result in a population decline. 
In general, antibiotics, prescription drugs and reproductive hormones 
have been found at similar detection frequencies and non-prescription drugs at 
higher frequencies. This is almost certainly because the latter have a higher 
annual use compared to the other pharmaceuticals (Kolpin et al, 2002). 
However, even at low levels, effects can occur: levels as low as <0.001 pg/l of 
reproductive hormones (e. g. ethinylestradiol; Lange et al, 2001) have been 
shown to have deleterious effects in aquatic organisms. Also, it is not currently 
known what the effects of long-term exposure are, both on adult fish and during 
the different stages of the life cycle (for example, during development). 
The occurrence of these pharmaceuticals in the environment has 
instigated numerous studies all over the world. Various classes of prescription 
drugs have been detected at up to pg/I levels in sewage, surface and ground 
water, and these results are discussed below. 
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1.4.2 Contraceptive steroids 
Natural and synthetic oestrogens are amongst the most frequently used 
drugs and these contribute to the highly publicised oestrogenic effects of 
sewage effluents on fish (Purdom et al, 1994, Harries, et al, 1997) and other 
wildlife (Colborn et al, 1992,1996). Many studies have consequently been 
carried out to look for effects of these oestrogenic chemicals. Effects reported 
have included feminisation in male fish (Jobling et al, 1998), skewed sex ratios 
(Sumpter and Pickering, 2005), oocytes in the testes of male fish living 
downstream from sewage treatment works (Nolan et al, 2001), male fish 
producing vitellogenin (Purdom et al, 1994), retardation of the growth and 
development of the testes in maturing male fish (Jobling et al, 1995), and 
reduction of the number of eggs oviposited in female fish (Harries et al, 2000; 
reviewed in Tyler et al, 1998). 
Although generally low, significant levels (i. e. biologically active) of 
synthetic oestrogens such as ethinylestradiol (EE2) and mestranol have been 
found in sewage effluents (ENDS, 2000). These synthetic steroids are often 
prescribed as oral contraceptives, but because of their very high potency, the 
total amounts sold are relatively low (Heberer, 2002). In Germany, Ternes et al 
(1999) predicted that annual prescriptions only totalled 50kg EE2/year. This 
indicates that the levels expected in the environment would only be in trace 
amounts (low ng/I range), and this has generally been shown to be true. 
Synthetic oestrogens have been reported in UK sewage effluent (Desbrow et a/, 
1998, Aherne and Briggs, 1989) at levels from non-detectable to 7.0 ng/l, with 
the majority of the samples having concentrations below detection limits. 
Belfroid (1999) and Larsson (1999) identified Dutch and Swedish levels which 
were similar to those in the UK (7.5 ng/I and 4.5ng/l, respectively). In 1999, 
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however, Ternes et al reported quite high levels compared with the UK, with 
concentrations of EE2 from non-detectable to 42 ng/I in Canadian effluents (with 
the median being 9ng/I) and 15 ng/l in German effluents. Stumpf (1996) found 
17ng/I (median) in German sewage effluents, with the maximum being 62ng/l. 
Generally, the levels of EE2 found in the UK, Germany, the Netherlands and US 
are usually between I and 3 ng/I (and usually lower - below detection limits) in 
both sewage effluent and influent (Heberer, 2002). However, although these 
synthetic hormones are found at trace levels, effects of these hormones have 
been shown to occur in fish in vivo at levels as low as 0.1 ng/I (Purdom et al, 
1994). 
In rivers, the highest level of EE2 reported was by Kolpin et al (2002), 
who reported levels up to 830ng/l with a median of 73ng/1 of EE2 in 139 USA 
rivers (although these levels were considered to be incorrect by Ericson et al 
(2002) based on usage levels, and the data were consequently found to be 
erroneously published and maximum values were actually 273ng/I with a 
median of 94ng/I). Belfroid et a/ (1999) reported that rivers and other water 
bodies in the Netherlands that received treated wastewater contained <0.1- 
4.3ng EE2/I. In Italy, concentrations of 0.04ng/I (less than the limit of detection) 
were reported, downstream from a sewage treatment plant, on the river Tiber 
(Baronti et al, 2000). In 1996, Stumpf et al detected a maximum concentration 
of 4.3ng/l, and in 1989, Aherne and Briggs reported 2-15ng/I in UK rivers. 
A more worrying finding was that reported by Alder et al (2001), who 
reported a positive detection of EE2 in German ground and drinking water, with 
levels up to 2.4ng/l. 
Mestranol has only been sporadically detected in the environment 
(sewage effluent) at concentrations up to Ong/I (Ternes, 1998). Mestranol itself 
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is not oestrogenic, but it is metabolised in the body into EE2, which is 
(Christensen, 1998). 
Along with the synthetic oestrogens, there has also been a significant 
amount of focus on natural oestrogens in recent years, including 17p-oestradiol, 
oestrone, oestriol, and their possible involvement with the endocrine disruption 
issue in wildlife. Natural steroid oestrogens are very potent (although not as 
potent as their synthetic counterparts) and have biological activity at low 
concentrations, including effects on spermatogenesis and regression of the 
testis (Billard, et al, 1981). 
Levels of natural steroids found in sewage treatment effluents include 
reports of 17ß-oestradiol from 1-50ng/I and oestrone from 1-80ng/I (Shore et al, 
1993; Stumpf et al 1996; Desbrow et al, 1998). Ternes et al (1999) reported 
concentrations of oestrone and oestradiol at mean levels of 70ng/l and 3ng/I, 
respectively, in German treated effluents, and Canadian effluent at 48 ng/I and 
64ng/I, respectively. Belfroid et al (1999) also detected levels in the 
Netherlands of 47ng/I and 1-12ng/I. 
In surface waters, levels of oestrone (0.7-1.6ng/I) and 17p-oestradiol 
(5ng/I) have also been reported in German rivers and streams (Belfroid et a/, 
1999; Ternes et a/, 1999). Although 1713-oestradiol is used therapeutically for 
hormone replacement, it is metabolised and excreted in the same way as 
endogenous 17(3-oestradiol. Natural excretion of endogenous hormones is 
thought to be the main route of entry of the oestrogens into the environment 
(women excrete between 10 and 100pg of oestrogen daily, depending on the 
phase of their menstrual cycle, and pregnant women excrete even more). 
The presence of these oestrogens (both natural and synthetic) is very 
important, as levels detected have been shown to produce effects in fish, and 
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consequently have the potential to affect wild populations of aquatic organisms 
(reviewed in Tyler et al, 1998). 
1.4.3 Antidepressants 
Antidepressants have been shown to be present in the environment and 
have also been shown to have effects on organisms living in it. The drugs 
found include selective serotonin reuptake inhibitors (SSRIs), which in people 
increase the levels of serotonin in the brain by preventing reabsorption. 
Because of the critical nature of the functions of serotonin, there is the potential 
for environmental SSRIs to alter appetite, the immune system, reproduction, as 
well as other behavioural functions, in organisms that receive exposure. There 
are therefore many potential effects of chronic exposure. 
In surface waters and municipal effluents, fluoxetine (the active 
ingredient of Prozac) has been detected at levels of 0.012 and 0.540pg/l, 
respectively, although the magnitude and prevalence in the environment has 
not been fully explored (Brooks et al, 2003). Fluoxetine has been shown to 
induce spawning in mussels at levels below 1 pg/l, increase egg size in 
crustaceans and alter sex organ maturation in crabs. It has also been shown to 
affect behaviour in animals such as squid and lobsters (Brooks et al, 2003). 
The fluoxetine metabolite, norfluoxetine, has not yet been reported in the 
environment. 
1,4,4 Analgesics/Anti-inflammatories 
Among the drugs found in the environment, the nonsteroidal, anti- 
inflammatory drugs (NSAIDs), including compounds used as analgesics, belong 
to one of the most important groups of pharmaceuticals world wide, with an 
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estimated annual production (based on the number of prescriptions) of several 
kilotons (Cleuvers, 2004). In addition to this, some of these drugs are bought 
without prescription, so the actual consumption is considerably higher. Of these, 
paracetamol (acetaminophen) and aspirin (acetylsalicylic acid - ASA) are the 
two most popular over-the-counter drugs. Webb (2000) reported that the drug 
used the most in the UK was paracetamol (2000 tonnes/annum) with aspirin 
next (770 tonnes/annum). ASA has been reported to be readily degraded by 
deacetylation into its more active form, salicylic acid, and into two other 
metabolites, ortho-hydroxyhippuric acid and the hydroxylated metabolite 
gentisic acid. Salicylic acid, ortho-hydroxyhippuric acid and gentisic acid were 
reported by Ternes (1998) to be present in sewage influent at concentrations up 
to 54,6.8 and 4.6pg/l, respectively. He also observed that all three compounds 
were efficiently removed by the sewage treatment process, and only salicylic 
acid was detected at very low levels in sewage effluent and rivers. Heberer (in 
press), however, recently reported that residues of salicylic acid in the 
environment are not necessarily from ASA, they could also be from ketatolytic, 
dermatice, natural formation and food preservatives. 
In 1996, Stumpf et al identified diclofenac (<1.59pg/1), ibuprofen 
(<3.35pg/1), and ASA (1.51pg/l) in sewage, with lower levels (0.01-0.5pg/I) in 
river waters. Diclofenac and ibuprofen have also been detected at very low (1- 
6ng/l) levels in drinking water. In Germany, diclofenac, ibuprofen and 
phenazone residues have also been detected at trace levels in a few drinking 
water samples (Heberer, 2002; Heberer et a/, 2001; Ternes, 2001). Ternes 
(1998) also reported concentrations of diclofenac, ibuprofen, naproxen, ASA 
and other compounds (some at concentrations >1 pg/l) in wastewater treatment 
plants and at lower concentrations in surface waters. Furthermore, in long term 
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monitoring programs of sewage and surface waters samples in Germany, 
Heberer et a/ (2002) reported diclofenac as one of the most important 
pharmaceutically active chemicals present in the water cycle. Average 
concentrations were found to be 3.02pg/l (influent) and 2.51 pg/I (effluent). 
Additional findings of diclofenac and ibuprofen have been reported from Swiss 
lakes and rivers (Buser et a/, 1998a, b), Brazil (Stumpf, et a/, 1999), Spain (Farre 
et a/, 2001), Greece and the United States (Heberer et a/, 2001). 
Other analgesics (4-aminoantiyrine, aminophenazone, codeine, 
fenoprofen, hydrocodone, indometacine, ketoprofen, mefenamic acid, 
naproxen, phenazone and propyphenazone) have also been detected in 
sewage and surface waters (Heberer, 2002; Heberer et al, 1997,2001; Ternes, 
1998; Stumpf, eta/, 1996). 
1.4.5 Anti-epileptics 
Anti-epileptic drugs (such Carbamazepine and Primidone) represent the 
most dominant of all investigated drugs in well-treated domestic effluents in 
Arizona and California (Jos et al, 2003). They have been shown to be 
persistent (the removal of the drugs did not seem to occur during travel times of 
more than 6 years in the subsurface: Drewes et al, 2002). Carbamazepine has 
frequently been detected in municipal sewage plant effluents at concentrations 
up to 6.3µg/l (Ternes, 1998), in surface samples up to 1.075µg/l, and in ground 
water samples up to 1.1 pg/I, and even in drinking water up to 30ng/l (Heberer, 
2002). Primidone has also been found in samples from municipal sewage 
influents and effluents and in surface waters (up to 635ng/I) in Germany 
(Heberer, 2002; Heberer et a/, 2001). 
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Jos et al (2003) state that there are very few reports on the effects of 
Carbamazepine on aquatic organisms. The results they presented were similar 
to those from Jones et al (2002) who reported that Carbamazepine is toxic for 
cnidaria and non-toxic for crustaceans and fish. 
1.4.6 p-blockers 
Another class of drugs present in the environment is the beta-adrenergic 
receptor-blocking compounds (p-blockers), which are extensively used to treat 
angina and hypertension (Ternes, 1998). These compounds act by binding and 
blocking the ß receptor, without causing receptor activation or stimulation. There 
are different types of ß-blocker, some specific e. g. metoprolol and atenolol, 
which act via for the ßi receptor, and some non-specific, e. g. propranolol and 
nadolol, which have a similar affinity for both (3, and 132 receptors. In organisms 
that lack ß adrenoreceptors, ß blockers cannot pharmacodynamically affect 
them (Jones, 2002). Fish have been shown to have ß receptors, including 
various types, in several of their tissues (Huggett et al, 2002), and thus in theory 
p-blockers could affect these organisms. 
After ingestion, approximately 10% of the parent compound is excreted 
(although in the case of atenolol, almost all of the ingested drug is excreted 
unchanged). Consequently, several beta blockers (e. g. metoprolol, propranolol, 
betaxolol, nadolol and bisoprolol) have been detected in European sewage 
effluents at concentrations up to the pg/l level (Hirsch et al, 1988; Ternes, 1998; 
Sedlak and Pinkson, 2001). Of these, metoprolol, propranolol and bisoprolol 
have also been found in surface water samples (Hirsch et al, 1988; Ternes, 
1998). Sacher et al, (2001) reported that sotalol was detected in three 
groundwater samples from Germany - to a maximum concentration of 560ng/l. 
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Huggett et al (2002) reported levels in the US to be comparable to those in 
Europe; propranalol in wastewater effluents was present at concentrations up to 
1.9pg/I and metoprolol and nadolol 1.2 and 0.36pg/I, respectively. To date, p- 
blockers have not been reported in any drinking waters. 
From exposure studies using fish, Huggett et a/ (2002) concluded that 
the levels found in the environment represent a significant hazard. Effects on 
steroid hormone concentrations, fecundity and egg viability were reported after 
a 2-week exposure to lpg propranolol/I. It is thought that because of their low 
but persistent presence in the environment, these compounds are more likely to 
have chronic effects, such as behavioural changes, rather than acute toxic 
effects. 
1.4.7 Contrast media 
Contrast media are not strictly pharmaceuticals, in that they are not given 
to patients to treat illness; instead, they are administered during the diagnosis of 
disease. Iodinated X-ray contrast media are some of the most frequently 
applied compounds in medicine. They have been identified by Gartiser et al 
(1996) as the main contributor to the loads of total adsorbable organic halogens 
in clinical wastewaters. In all countries where there is a developed medical care 
system, it can be expected that X-ray contrast media are present at appreciable 
quantities in sewage effluents and hence contamination of receiving waters is 
possible. Iodinated contrast agents are very persistent in the environment and 
also easily leach into the groundwater aquifers. In sewage effluents, ground 
and surface waters they have been detected at concentrations up to pg/I, and in 
some cases they have also been found in drinking water (Heberer, 2002). 
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1.4.8 Cytostatic drugs 
Cytostatic drugs are frequently used in chemotherapy and, therefore 
mainly originate from hospital applications. Hospital sewage has been shown to 
contain concentrations of these drugs up to low pg/I levels (Steger-Hartmann et 
a/, 1996). In effluents from municipal sewage treatment plants receiving and 
purifying hospital effluents, they have been found at trace concentrations, 
mostly at the low ng/I level. They have not yet been detected in surface or 
drinking waters. 
Due to their pharmacological potency, cytostatic drugs often exhibit 
carcinogenic, mutagenic or embryotoxic properties and consequently their 
presence in the environment could be potentially hazardous. 
1.4.9 Antibiotics 
Antibiotics are also an important group of pharmaceuticals, due to the 
scale of their ubiquitous use worldwide. In addition to the treatment of human 
infections, they are also widely used in veterinary medicine (Hirsch et al, 1999) 
and sometimes incorporated in the feed as growth promoters in farming 
livestock. They are probably the most discussed of the pharmaceuticals 
because of their potential role in the spread and maintenance of (multiple) 
resistance of bacterial pathogens. This poses a serious threat for public health, 
as more and more infections can no longer be treated with current antibiotics. 
Epidemic diseases in hospitals are often caused by resistant strains and at 
present, more than 70% of all bacteria are insensitive against at least one 
antibiotic, and many show multiple resistance. 
Some 5,400 tonnes of antibiotics were used in human medicine in the 
EC in 1997 (ENDS, 2000), whilst veterinary use totalled 5,100 (including 3500 
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tonnes of medicines and 1600 tonnes of growth promoters). Although not very 
persistent in the environment (these drugs have half lives of a few days or 
weeks), they are very prevalent, especially in surface waters, as they are 
soluble and are washed out of the soil. Macrolide antibiotics (e. g. 
clarithromycin, dehydro-erythromycin [a metabolite of erythromycin], 
roxithromycin, lincomycin), sulfonamides (sulfamethoxazole, sulfadimethoxine, 
sulfamethazine, and sulfathiazole), fluoroquinolones (ciprofloxacin, norfloxacin, 
and enrofloxacin), chloramphenicol, tylosin, and trimethroprim have been found 
at concentrations up to the low pg/I level in sewage and surface waters 
(Heberer, 2002; Golet, et al, 2001,2002). However, when monitoring 
investigations of various sewage, surface and ground water samples in 
Germany were carried out by Hirsch et a/ (1999), they did not detect penicillin or 
tetracycline. This result was not surprising, as penicillins are easily hydrolysed 
and tetracyclines readily precipitate with cations such as calcium and hence 
tend to accumulate in sewage sludge or sediment. 
The environmental concerns of antibiotics are not only based on the 
potential of resistance but also on their unfavourable ecotoxicological profile 
(Hailing-Sorensen, 2000). There are no publications to date on the issue of the 
development of resistance of bacteria to the levels of antibiotics present in the 
aquatic environment. 
1.4.10 Lipid lowering drugs 
The first ever pharmaceutical detected in the aquatic environment was a 
lipid lowering drug, first detected in 1976. Since then, bezafibrate, gemfibrozil, 
clofibric and fenofibric acids (the metabolites of clofibrate and fenofibrate) have 
all been detected at concentrations up to the pg/I level in sewage effluents and 
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surface waters (Ternes, 1998; Stumpf et al, 1999; Heberer et al, 2001; Stan and 
Heberer, 1997). Bezafibrate and gemfibrozil have also been found in ground 
water samples at maximum concentrations of 190 and 340ng/l, respectively 
(Ternes, 2001; Heberer, 2002). 
The first lipid lowering drug, cholestyramine, was approved for use in 
1964. Clofibrate and dextrothyroxine were released in 1967, followed by 
colestipol and probucol in 1977 (Clinical pharmacology online, 2000 - 
www. cponline. gsm. com). Hence, these drugs have probably been present in 
the environment for the last few decades. 
Antilipidemic agents can be subdivided into bile acid sequesterants 
(cholestyramine, colestipol), HMG-CoA reductase inhibitors (fluvastatin, 
lovastatin, pravastatin and simvastatin), fibric acid derivatives (clofibrate and 
gemfibrozil), and some miscellaneous agents (dextrothyroxine, nicotinic acid 
and probucol). They act in humans either by reducing the production of 
lipoproteins or by increasing their removal from the blood. The overall effect is 
to decrease plasma cholesterol levels. 
Although there are several chemically unrelated classes of lipid lowering 
drugs, they all reduce lipoprotein fractions by interfering with the absorption, 
synthesis and/or metabolism of cholesterol and lipoproteins. Eghdamian and 
Ghose (1998) state that lipid lowering drugs may be effective in reducing lipids 
and lipoproteins by one of the following ways: 
1. by reducing the synthesis of VLDLs and LDLs 
2. by enhancing VLDL clearance 
3. by enhancing LDL catabolism 
4. by inhibiting the HGM-CoA reductase enzyme 
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As this thesis focuses on the possible ecotoxicological effects of clofibric acid, 
this drug will be discussed in greater depth. 
1.5 Clofibrate and Clofibric acid 
1.5.1 Background 
Clofibrate (ATROMID-S) is an orally administered antilipemic agent; the 
parent compound was discovered during the screening of aryloxyacetic acid 
derivatives. It was licensed for human use in 1962 and given FDA approval in 
1967 (Catapano, 1995; Clinical pharmacology, 2000). Since then, second, third 
and fourth generation compounds have been developed with higher potency 
and fewer side effects. 
Figure 1.2: The structure of Clofibrate. 
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Clofibric acid (Figure 1.3) is the major metabolite of the lipid lowering 
drugs Clofibrate (Figure 1.2), Etofibrate and Etofyllinclofibrate. It is structurally 
similar to the herbicide Mecoprop. 
Figure 1.3: The structure of Clofibric acid. 
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Table 1.2: Physical properties of Clofibrate and Clofibric acid. 
Name Chemical 
formula 
Molecular 
weight 
Solubility Log K. CAS RN 
Insoluble in 
Clofibrate C12H15CIO3 242.7 water, soluble in 3.62(sanderson 637-07-0 
DMSO or ETOH at at, 2003) 
Clofibric C10H11CI03 214.04 582.5 mg/I (Ferrari 2.57(Ferrari at 882-09-7 
Acid at al, 2003) a/, 2003) 2.84(Sanderson 
at al, 2003) 
As already mentioned, clofibric acid was the first prescription drug 
metabolite ever reported in sewage influent and effluent in Kansas City, USA in 
1976 (Hignite and Azaznoff, 1977). It was detected in the environment, as a 
consequence of the routine analysis for acidic pesticides (Ayscought, et al, 
2000), and is still the most frequently detected drug in sewage effluents, ground 
water, surface and drinking water all over the world (Koutsouba et al, 2003). 
1.5.2 Motility 
Clofibric acid has been found to be highly motile and very persistent in 
the environment (a half life of 21 years has been reported), because it is non- 
biodegradable (Richardson and Bowron, 1985). It is still detected in lakes and 
rivers, even though Clofibrate is rarely prescribed nowadays as other drugs 
have replaced it (Zuccato, 2000; IARC, 1996). It has been found to have a 
water residence time of 1-2 years (Buser and Muller, 1998), whereas in human 
plasma the half-life is about 17 hours, from where it is excreted in the urine, 
predominantly in the form of a glucuronide conjugate. 
The presence of clofibric acid in the environment is summarised in Table 
1.3, which shows that most measurements have been made in Germany. In 
addition to these records, it has been detected down to depths of 125m below 
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sewage farm areas in Germany (Heberer, 2002). The results are relatively 
consistent: clofibric acid is often detected in aqueous samples, usually at 
concentrations in the high ng/I range, but occasionally in the low Ng/I range. 
In laboratory experiments using soil columns, Scheytt et al (2001) found 
that clofibric acid did not show any significant sorption. It leached almost tracer- 
like through the soil columns without retardation (Heberer, 2002). This is 
confirmed by other studies, where clofibric acid was reaching water supply wells 
without being removed in the subsoil (Heberer et a!, 2001). Concentrations of 
bezafibrate, on the other hand, have been found to be easily attenuated during 
bank filtration (Heberer et al, 2001). 
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Table 1.3: Concentrations of Clofibric acid present in the environment. 
Adapted from Schulman, 2002. Where ND - Not detected; NA - Not 
available; LOD - Limit of detection; *- Median, 90 percentile; *** - maximum; 
- median maximum; +- positive identification but concentration not quantified. 
Compound Medium Number of samples 
Conc. 
detected SOD (n9/1) Country Reference Year 
Clofibrate Sewage 20 ND 100 Germany Temes 1998 
Clofibrate 5 ND 1 Germany Kalbfus 1997 
Clofibric acid 7 2540-9740 140 Us Hignite & Azamoff 1977 
Clofibric acid NA 3pg/I NA USA Garrison 1976 
Clofibric acid NA Up to 4550 NA Germany Stan & Heberer 1997 
Clofibric acid NA ND-2050 250 Germany Stan & Heberer 1997 
Clofibric acid NA ND-1030 NA Germany Stan & Heberer 1997 
Clofibric acid 37 270,660,1560" 50 Germany Stumpf et at 1998 
Clofibric acid NA 450,680 NA Germany Heberer et at 1998 
Clofibricacid 49 360,720,1600* 40 Germany Temes 1998 
Clofibric acid NA 102,1030" 50 Brazil Stumpf et at 1999 
Clofibric acid 18 ND NA Canada Metcalf 2003 
Clofibric acid 5 420"" 1 Germany Kalbfus 1997 
Clofibrate Surface 36 ND 30 Germany Temes 1998 
Clofibrate 10 ND 0.5 Germany Kalbfus 1997 
Clofibrate NA 40 5-10 UK Richardson & Bowron 1985 
Clofibric acid NA ND-1750 I Germany Stan & Heberer 1997 
Clofibric acid NA 140-180 NA Germany Stan & Heberer 1997 
Clofibric acid NA ND-300 1 Germany Stan & Heberer 1997 
Clofibric acid NA 180"* 5 Germany Stumpf et a/ 1996 
Clofibric acid 28 ND-875 NA Germany Heberer et al 1998 
Clofibric acid 43 68,210,550" 10 Germany Temes 1998 
Clofibric acid NA 19-222 1-10 Germany Stan, Heberer at at 1994 
Clofibric acid 0.01-1.35,18 
Germany/ 
North sea Weigel et at 
2002, 
2003 
Clofibric acid NA ND-9 NA Switzerland Buser et al 1998 
Clofibric acid 10 ND I Germany Kalbfus 1997 
Clofibric acid NA 90"' 10 Brazil Stumpf, Teures et al 1999 
Clofibric acid NA 30 NA Italy Herberer & Stan 1997 
Clofibric acid NA ND 1.5 Italy Zuccato et a/ 2000 
Clofibrate Ground 3 ND 0.5 Germany Kalbfus 1997 
Clofibric acid 17 70-7300 NA Germany Heberer et al 1997 
Clofibric acid NA 4000 NA Germany Herberer & Stan 1997 
Clofibric acid 3 ND 0.5 Germany Kalbfus 1997 
Clofibric acid NA 300-1600 NA Germany Bouwer 1982 
Clofibric acid 18 -50-2900 NA Germany Heberer et at 1997 
Clofibrate Drinking 3 ND 0.5 Germany Kalbfus 1997 
Clofibric acid NA + NA UK Fielding et a/ 1981 
Clofibric acid 25 1,24,70" 1 Germany Stumpf et al 1996 
Clofibric acid NA 165'"" 1-10 Germany Stan at at 1994 
Clofibric acid 3 ND 0.5 Germany Kalbfus 1997 
Clofibric acid NA ND-170 NA Germany Herberer & Stan 1997 
Clofibric acid NA 270"' 1 Germany Herberer & Stan 1996 
Cloflbric acid NA ND-5.3 1.5 Italy Zuccato eta! 2000 
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1.5.3 Usage 
The recommended human clinical dose of Clofibrate is 2g daily, 
delivered as 2-4 doses (Boyd, 2001; IARC, 1996); the lowest clinically active 
dose is reported to be 500mg/day (Perlemuter et a/, 1975). Currently in the UK, 
it is difficult to obtain a reliable estimate of the use of clofibrate in tonnes per 
year, as it is not regularly prescribed, although it has been reported that in 1995 
it was 1.5 ton/annum. In Germany, however, in 1992-3 it was 30 ton per year. 
The Ends report (2000) states that clofibric acid loads imposed on typical 
sewage works are estimated in the order of kilograms per day. The removal rate 
in sewage treatment works (STW) has been found to be 15-51% (Schowanek 
and Webb, 2002). Clofibric acid has a lower bioaccumulation factor (BAF) (372) 
than Clofibrate (4170), therefore the ambient water quality criteria (AWQC) is an 
order of magnitude higher (1.93 and 0.22mg/I, respectively; Schulmann, 2002). 
Although no longer used in the UK (as other lipid lowering drugs have 
replaced it), Clofibrate is still widely used in France (Laville, 2003). Having said 
this, it is reported (Ferrari, 2003) that Clofibric acid has not recently been 
detected in effluents from Lyon in France, perhaps because it has been 
replaced with fenofibrate, bezafibrate or gemfibrozil in that country. 
1.5.4 Mode of action 
In humans, Clofibrate has been found to reduce elevated plasma 
concentrations of triglycerides by 30-60%, by up-regulation of lipoprotein lipase 
(LPL) and, to a lesser extent, cholesterol by 20-25% (Blane, 1987). It has also 
been associated with a moderate decrease in LDL cholesterol and an increase 
in HDL cholesterol (Staels et al, 1998). It is not effective in patients with high 
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plasma cholesterol but a normal triglyceride concentration (Eghdamian and 
Ghose, 1998). 
The wide spectrum of lipid modulating actions of fibrates is mediated by 
their capacity to mimic the structure and biological functions of free fatty acids: 
they interfere with fatty acid synthesis, and stimulate hepatic fatty acid 
oxidation, thus reducing the amount of fatty acid available to the liver for 
triglyceride synthesis. They can inhibit cholesterol biosynthesis by blocking 
incorporation of acetate into cholesterol; they induce the hepatic uptake of 
cholesterol from plasma and enhance its elimination in the bile as bile acids and 
they also increase lipoprotein lipolysis by inducing liver LPL expression and 
lowering Apo CIII production (Guo et al, 2001). 
Fibrates are known to act at the molecular level by altering transcription 
of genes encoding for proteins involved in lipid metabolism (Staels et al, 1998). 
This is facilitated by them activating specific transcription factors, the 
Peroxisome Proliferator Activated Receptors (PPAR), which are members of the 
nuclear hormone receptor family of transcription factors (see Figure 1.4). These 
bind specifically to response elements in the regulatory regions of a spectrum of 
target genes, causing them to be up or down regulated (Chapman, 2003; see 
Figure 1.4 and Table 1.4). 
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Figure 1.4: Mechanisms of action of fibrates. PPARcL exerts its multiple 
effects in the liver, heart and vessel wall of humans and rodents by 
regulating expression of corresponding genes (Kota et at, 2004). Fibrates 
reduce triglyceride concentrations by changing the transcription rates of 
different genes (PPAR: Peroxisome Proliferator-Activated Receptor; PPRE: 
Peroxisome Proliferator Response Element; RXR: Retinoid X Receptor; TG: 
Triglyceride). 
Table 1.4: Major genes implicated (in humans) in the PPAR-mediated 
action of fibrates on lipid metabolism (adapted from Chapman, 2003). 
Target Gene Function of gene product Gene expression 
Apolipoprotein CIII Inhibitor of VLDL clearance J, 
Lipoprotein lipase Lipolysis, TGRL T 
Apo Al HDL formation T 
Apo All HDL formation T 
Fatty acid binding Cellular fatty acid uptake T 
protein 
Acyl CoA synthase Fatty acid activation; acyl CoA T 
esters 
ß-oxidation pathway Fatty acid oxidation T 
Acetyl CoA carboxylase Fatty acid synthesis I 
PPARs are known to be key messengers in the translation of nutritional, 
metabolic and pharmacological stimuli into changes in gene expression 
(Schoonjans et al., 1997), and are primarily involved in energy balance, 
modulating fatty acid oxidation in liver and lipid accumulation in adipose tissue 
(Latruffe and Vamecq, 1997). PPAR genes have been previously identified in 
Atlantic salmon and plaice (Ruyter et al., 1997; Leaver et al., 1998) and thus 
probably also have a role in regulating lipid metabolism in fish. In fact, Perkins 
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and Schlenk (1998) suggested that after a 24hr waterborne exposure to 
Clofibric acid (0,10,50,100,225mg/I), catfish display a PPAR response similar 
to that observed in mammals. Chapter 6 goes into further detail on PPARs. 
1.5.5 Toxicology studies/Side effects in humans 
In humans the side effects of treatment with clofibrate include: nausea, 
headaches, dizziness, fatigue, drowsiness, weakness, fever, dry skin, breast 
tenderness in men, brittle hair, rash, alopecia, pruritus, toxic epidermal 
necrolysis, and erythema (AHFS, 2000). A decreased libido and impotence 
have also been reported (Martindale, 1999) and treatment has also been 
associated with hepatic tumours and certain cardiovascular disorders. 
In a study in 2001, Dietrich reported that the acute toxicity of clofibric acid 
in rat, mouse and human is between 800 and 1200 mg/kg. He also found that 
the chronic toxicity (found from a2 year rat study) of clofibric acid produced .a 
no observed adverse effect level (NOAEL) of 17-220 g/kg based on the 
cumulative dose. Along with this he also stated that chronic toxicity of clofibric 
acid induces promotion of liver tumours in rats, by the interaction of clofibric 
acid with the PPAR receptor. 
In reproduction studies it has been previously documented that doses 
approximately two times the maximum recommended human dose of clofibrate 
instigates the arrest of spermatogenesis in dogs and monkeys (RxList, 2002 - 
www. RxList. com), whereas Schulman et al (2002), suggest that this same effect 
occurs at four to six times the maximum recommended dose. 
Peroxisome proliferators (such as phthalates) have previously been 
shown to induce pathological changes in the reproductive system in rodents 
(and exert subtle effects on fertility and litter size). As fibrates are known 
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peroxisome proliferators, their effects may well be similar. Treatment with 
ciprofibrate has been shown to alter gene expression in the Leydig cells of rats, 
however no changes were seen in the seminiferous tubule or in peroxisomal 
volume. The treatment of Clofibrate has been found to alter cell growth, gene 
expression and inhibit progesterone synthesis in human cell lines (Gazouli et al, 
2002). 
It has also been shown by Gazouli et al (2002), in mouse cell lines, that 
peroxisome proliferators (Bezafibrate) exhibit antiandrogenic properties through 
the inhibition of the hormone-induced rate-delimiting step in steroid 
biosynthesis, the transport of cholesterol into the mitochondria. They found that 
the testicular Leydig cell is one of the target cells of peroxisome proliferators. 
Alterations of Leydig cell function and testosterone formation could lead to 
developmental defects in androgen-dependant tissues of the male reproductive 
system, directly affecting testicular function, spermatogenesis, and fertility in 
adults. 
1.5.6 Ecotoxicological information on Clofibric acid 
The majority of previous research that has been carried out to examine 
the effects of clofibric acid on aquatic organisms has been based on standard 
ecotoxicological tests for risk assessment. Henschel et al (1997) reported the 
results of toxicological studies carried out using clofibric acid (Table 1.5). They 
reported that cell cultures (derived from bluegill sunfish), fish embryos 
(zebrafish) and algae were all sensitive to clofibric acid, with EC50 values of 14, 
86 and 89 mg/I, respectively. Pulse rate tests carried out with Daphnia, fish 
embryos and ciliate proliferation found EC50s of around 100mg/I. Kopf (1995) 
found similar results with acute/short term tests with clofibrate and clofibric acid, 
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with lowest endpoint effects seen at 12mg/I and an EC50 of 89mg/I. Ferrari et al 
(2003) also carried out ecotoxicological bioassays to determine the effects of 
clofibric acid on six species (covering bacteria, algae, microcrustaceans and 
fish). They found that their 48hr EC50 values were more than 200mg/I for 
clofibric acid in daphnid and ceriodaphnid acute toxicity tests, but in chronic 
toxicity tests using rotifers, a no observed effect concentration (NOEC) of 
0.25mg/I was found, indicating they are far more sensitive and suggesting that 
non-target organism can be affected by clofibric acid. 
Exposure Assessment EC50 
Toxicity Test Species 
time Endpoint (Ng/I) 
Acute Bacteria V. fischen 30 mins Luminescence 100,000 
Ciliates T. pyriformis 48hr Growth 175,000 
Daphnids D. magna 48hr Mobility 106,000 
Fish 
D. rerio 48hr Mortality 86,000 
embryos 
Chronic Algae P. subcapitata 96hr Growth 89,000 
Cytotoxicity/ 
In vitro Fish cells BF-2 cells 48hr 14,000 
proliferation 
i aoie -im; ccotoxicoiogicai erects of clotibric acta. I aKen from Henschel et 
al (1997). 
A small number of chronic tests using algae and fish embryos have also 
been carried out (Ferrari et al, 2003), and these organisms have been shown to 
be less sensitive than invertebrates. The low sensitivity of fish may be 
explained by the procedure used, in particular the age of the embryo (as the 
permeability of the chorion affects the uptake of the chemicals and 
consequently their viability (see Chapter 3)). It is possible that current chronic 
tests may not necessarily detect specific or sensitive deleterious effects, as the 
protocols involve measuring only defined endpoints. More sensitive endpoints 
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need to be determined and used, rather than the traditional toxicological 
endpoints. 
In summary, the very limited amount of information currently available on 
the ecotoxicological effects of clofibric acid suggests that the drug is relatively 
non-toxic in acute studies (concentrations causing effects were very high - in 
the mg/I range). Almost nothing is really currently known about the chronic 
toxicity of clofibric acid, but this could be because present methods do not 
necessarily involve monitoring specific or more sensitive endpoints. 
1.6 Metabolism 
It is very important, when exploring the effects of any pharmaceutical 
drugs on an organism, to firstly look at the mechanisms that are involved in 
processing that drug in humans, as they are usually the ones that the drug has 
been designed to treat. It is therefore important to consider briefly the basic 
metabolism in humans, and then compare relevant areas with those that are 
also known in fish. 
Metabolism is the sum of the physical and chemical changes that take 
place in living organisms. These changes include both synthesis (anabolism) 
and breakdown (catabolism) of body constituents. In a narrower sense, it is the 
physical and chemical changes that take place to a given chemical substance 
within an organism. It includes the uptake and distribution within the body of 
chemical compounds, the biotransformations undergone by such substances, 
and the elimination of the compounds and their metabolites. 
Metabolism also enables absorbed products of digestion (glucose, fatty 
acids and glycerol, and amino acids) to be processed, and is essentially 
dependant upon the nature of the basic diet (carbohydrate, lipid and protein). 
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All of the products of digestion are processed by their respective pathways to a 
common product (acetyl-CoA), which is then completely oxidised by the citric 
acid cycle. 
1.6.1 Carbohydrates 
Carbohydrate in the diet is processed to glucose, which is then 
metabolised to pyruvate and lactate by glycolysis. This produces ATP, thus 
glucose is the major fuel of many tissues. It also takes part in other processes, 
including: 
1) storage to glycogen, 
2) the pentose phosphate pathway (see Section 1.6.1.1. ), 
3) the glycerol moiety 
4) the synthesis of the carbon skeletons for the synthesis of amino acids - 
acetyl CoA is the building block for long chain fatty acids and cholesterol - 
the latter being the precursor of all steroids synthesised in the body. 
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Figure 1.5: An overview of fatty acid metabolism, showing the major 
pathways and end products (adapted from Murray et al, 1993). 
1.6.1.1 The Pentose Phosphate Pathway 
The pentose phosphate pathway is an alternative route for the 
metabolism of glucose. It does not generate ATP, but instead has 2 major 
functions: 1) to generate NADPH for reductive syntheses (such as fatty acid 
synthesis and steroid biosynthesis), and 2) to provide ribose residues for 
nucleotide and nucleic acid biosynthesis (see Figure 6.1). Along with these 
major functions, it also has the very significant function of excretion of 
metabolites and foreign chemicals (xenobiotics) via the uronic acid pathway. In 
humans the pentose phosphate pathway is active in the liver, adipose tissue, 
adrenal cortex, thyroid, erythrocytes, testis and lactating mammary gland 
(Murray et al, 1993). Further details follow in Chapter 6. 
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1.6.2 Proteins 
Amino acids are necessary for protein synthesis. Some must be 
supplied from the diet (essential amino acids), as they are unable to be 
synthesised by the body. The others are also supplied by the diet, but can also 
be formed from intermediates by transamination using amino nitrogen from 
other surplus amino acids. After deamination, excess amino nitrogen is 
removed and the carbon skeletons that remain: - 
1) are oxidised (via the citric acid cycle) 
2) form glucose 
3) form ketone bodies 
In addition to protein synthesis, amino acids are also precursors for many 
other compounds - including hormones. 
Amino acids resulting from digestion of dietary protein and glucose 
resulting from the digestion of carbohydrates are directed to the liver. The 
glucose is converted into glycogen by glycogenesis or to fat by lipogenesis 
(Figure 1.5). The liver draws on these glycogen stores between meals to 
replenish glucose in the blood. 
1.6.3 Lipids 
Lipids in the diet are represented mainly by triacylglycerols, which upon 
digestion form monoacylglycerols and fatty acids. These are then recombined 
with proteins and released into the circulation as lipoproteins (chylomicrons). 
All hydrophobic, lipid soluble products of digestion form lipoproteins, which 
facilitates their transport in the plasma between tissues. Unlike amino acids 
and glucose, chylomicrons are not taken up directly by the liver, but are first 
metabolised by extra-hepatic tissues, by lipoprotein lipase (LPL), (further details 
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follow in Chapter 6), which hydrolyses the triacylglycerol, releasing the fatty 
acids that are incorporated into tissue lipids or oxidised as fuel. Surplus 
triacyiglycerol arising from both lipogenesis and free fatty acid is secreted into 
the circulation as VLDL, where it undergoes a similar fate to chylomicrons. 
In the tissues, fatty acids may be oxidised to acetyl-CoA (ß-oxidation) or 
esterified to acyiglycerols where, as triacylglycerol (fat), they constitute the 
body's main calorific reserve. Acetyl-CoA formed by ß-oxidation has several 
fates: 
" Acetyl-CoA derived from carbohydrate is oxidised and used in the citric 
acid cycle, where it is used to produce ATP, providing the tissue with 
energy. 
" It is a source of the carbon atoms in cholesterol and other steroids 
" In the liver it forms ketone bodies (water soluble fuel for certain 
conditions, e. g. starvation) 
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Figure 1.6: Structure of a plasma lipoprotein (from Thain and Hickman, 
2000). 
33 
Lipids are insoluble in water, and hence they have to be transported in 
the blood as lipoprotein complexes. These are defined as a micellar complex of 
protein and lipids. The protein component of these complexes (apolipoproteins) 
transport otherwise insoluble lecithin, triglyceride and cholesterol in blood 
plasma. The lipoprotein particle comprises an outer lipid bilayer with specific 
conjugated protein components, within which the transport molecules are either 
free or esterified to bilayer fatty acids (Figure 1.6; Thain and Hickman, 2000). 
Fish, unlike mammals, utilise lipids in preference to carbohydrate as their 
main source of energy (Wantanabe, 1982), and therefore tend to have high 
levels of lipoprotein in their plasma, reflecting this high utilisation of lipid. They 
are capable of accumulating considerable amounts of lipid in muscle and liver, 
as well as adipose tissue, for their energy reserves (Sheridan, 1988). 
Metabolic studies of plasma lipids and lipoproteins in fish remain limited; 
nevertheless, existing data suggest that the process and mechanisms involved 
in their metabolism have features in common with those of mammals. Fish 
lipoproteins are separated into four classes, which are similar to those of other 
vertebrates (Babin and Vernier, 1989). They consist of very low-density 
lipoproteins (VLDL), intermediate lipoproteins (IDL), low-density lipoproteins 
(LDL) and high-density lipoproteins (HDL) (Santulli et al, 1996). Babin and 
Vernier (1989) and Wallaert and Babin (1994) state that, in fish, the percentage 
of total lipids in each class of lipoproteins is comparable to that observed for 
humans, although HDLs predominate in the lipoprotein profile of fish (Ando, 
1996). 
When compared to standards for mammals, and humans in particular, 
fish are classified as hyperlipidemic and hypercholesterolemic (with elevated 
LDL levels) and in female oviparous species vitellogenin (a VHDL) causes the 
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fish to appear lipoproteinemic. Rainbow trout have been shown to carry three 
times (and sometimes up to a maximum of twelve times) more lipid and 
cholesterol in the blood than fed rats (Babin and Vernier, 1989). Most of the 
cholesterol is present in the plasma of most fish species in the esterised form. 
There are very little data concerning the quantitative changes of fish 
lipoproteins in response to varying external factors. A large body of work, 
however, has shown that the plasma concentration of lipids, particularly 
cholesterol and triglycerides, in fish is highly dependant on their nutritional or 
physiological state, their sex and on their developmental stage (Babin and 
Vernier, 1989; lijma et al, 1985; Santulli et al, 1991). Factors such as age and 
growth, sex, temperature, salinity or certain endocrine factors (such as 
concentrations of plasma steroid hormones), can also affect plasma cholesterol 
concentrations in fish (Babin and Vernier, 1989). It is therefore very important 
that fish entering any laboratory experiment are all of a similar physiological and 
nutritional condition and have all been treated in exactly the same way before 
beginning any experiment. 
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1.7 The Reproductive system of fish 
The effects of peroxisome proliferators (such as fibrates) on reproductive 
endpoints in humans and rodents have been mentioned previously. It is 
therefore important for me to describe the basic reproductive biology of fish, as 
various reproductive parameters were considered during experimental protocol 
in this thesis. 
1.7.1 Basic reproductive endocrinology 
The endocrine system of fish, just as in mammals, consists of a complex 
interaction of external stimuli, hypothalamic and pituitary hormones, gonadal 
hormones and deactivation of hormones by the liver (Kime, 1999). Sexual 
maturation and reproduction in fish are complex biological processes which are 
regulated by endogenous hormones, and synchronised by exogenous factors 
such as photoperiod and temperature, thus ensuring reproduction occurs at the 
optimal time for survival of the offspring. 
Fish differ from mammals in that the major testicular androgen is 11- 
keto-testosterone rather than testosterone (Kime, 1993), and whilst oestradiol is 
the ovarian oestrogen, it acts very differently than it does in mammals. Its major 
target tissue is the liver, which is stimulated by oestradiol to produce the yolk 
protein vitellogenin, which is incorporated into the oocyte under the influence of 
the gonadotrophin GtH-1 (Tyler et al, 1991), which is now usually called FSH, 
as in mammals. 
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Figure 1.7: Schematic diagram of the reproductive system in fish 
(GnRH - gonadotrophin releasing hormone, E2 - oestradiol, T- 
Testosterone, 17,200P - 17a, 200-dihydroxy-4-pregnen-3-one, 11-KT- 11- 
Ketotestosterone; LH - leuteinising hormone; FSH - Follicle stimulating 
hormone). Adapted from Kime, 1999. 
1.7.2 Steroid hormones 
The synthesis of steroid hormones is initiated by the conversion of 
acetate to cholesterol (Figure 1.5). This is the precursor of all steroid 
hormones. Cholesterol is transformed to pregnenolone (see Figure 1.8), which 
is itself metabolised by a sequence of enzymatic reactions to form the steroid 
hormones. As in rodents, HDL appears to be the main exogenous source of 
cholesterol for steroidogenesis in fish (Gilman et al, 2003). Cholesterol, 
testosterone and 1713-estradiol have relatively minor differences in chemical 
structure. These seemingly minor changes, however, result in profound 
difference in biological responses. 
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Figure 1.8: The principal pathways of steroidogenesis in fish. Where HSD 
= hydroxysteroid dehydrogenase. 
Oestrogens 
The most important of the `female' reproductive hormones are 170- 
oestradiol (E2) and oestrone (El) (Kime et al, 1995). They are secreted by the 
ovaries and are responsible for the control of sexual differentiation, secondary 
sexual characteristics and the oestrous cycle in mammals. In non-mammalian 
oviparous vertebrates, they play a vital role in oocyte development by inducing 
the synthesis of vitellogenin (Ng and Idler, 1983). The production of oestradiol 
in teleosts is based on a two-cell mechanism. The theca layer of the oocytes is 
stimulated by LH to produce androgens (Kagawa et al, 1982). These are then 
transported to the granulosa layer, where testosterone and androstenedione are 
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aromatised to E2 and El via the P450 aromatase enzyme, a process under the 
control of FSH. 
Androgens 
Androgens, or 'male' reproductive hormones, are responsible for the 
development of the male secondary sexual characteristics and reproductive 
behaviour, along with being essential for stimulating spermiation. The area of 
androgens and their effects on spermatogenesis is currently a highly active area 
of research in fish (Schulz and Miura, 2002; Miura and Miura, 2003). 
Androgens have been found to interact with nuclear receptors that 
modulate the expression of androgen receptor target genes, which have 
particular relevance for spermatogenesis (Schulz et al, 2001). These genes, 
however, have remained elusive and so the mode of actions of androgens in 
spermatogenesis remains unknown in both mammalian and non-mammalian 
vertebrates (Miura and Miura, 2003). 
The most active androgens in mammals are dihydrotestosterone and 
testosterone whereas in teleost fish it is 11-ketotestosterone (11-KT) (Kime, 
1993,1999). These are synthesised interstitially in the gonad, by the Leydig 
cells, (via the activation of the LH receptor) and are then metabolised to the 
more active compound in the Sertoli cells. As a male matures, gonadotrophin- 
releasing hormone (GnRH) from the hypothalamus stimulates the synthesis and 
release of leuteinising hormone (LH) and follicle stimulating hormone (FSH) 
(see Figure 1.7). LH acts on small groups of Leydig cells to stimulate the 
production of testosterone. Together with FSH, testosterone acts on the 
seminiferous tubules and promotes spermatogenesis (Kime et al, 1999; Schulz 
et al, 2002). 
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Testosterone and sperm production are controlled by negative feedback: 
as testosterone production increases, GnRH production decreases, and vice 
versa (Kime et al, 1999; Ostrander, 2000). In some mature male mammals, 
including humans, which reproduce throughout the year, testosterone and 
sperm production are continuous. In other species reproduction is seasonal. In 
these species, changes in day length and temperature affect the hypothalamus, 
growth and descent of the testis and the onset of the reproductive season. 
During the reproductive season, testosterone and sperm are controlled as they 
are in humans, but after the reproductive season GnRH is no longer 
synthesised, testosterone production falls and the testis become smaller and 
inactive until needed for the next season (Sherazi, 2000). 
Testosterone is also present in female teleost fish at high concentrations; 
in fact, it is often seen at higher levels than in the males (Borg, 1994). In 
females it is unclear what the role of testosterone is, although it has been 
suggested that it may be concerned with the maintenance of the oocyte 
maturation processes following vitellogenesis (Kime, 1993). 
As with oestradiol, testosterone is derived from cholesterol through a 
series of steps that are dependant on cholesterol availability and biosynthetic 
activity (see Figure 1.8). This biosynthetic activity is stimulated by LH from the 
pituitary. As shown in Figure 1.8, the key enzymes responsible for the 
synthesis of androgens are P450 cholesterol side chain cleavage (P450scc), 
3ß-hydroxysteroid dehydrogenase (3ß-HSD) and P450 17a-hydroxylase, 17-20- 
lyase (P450c17). 
11-KT is derived from testosterone (shown in Figure 1.8), and in some 
fish 11-KT has been shown to induce the entire process of spermatogenesis, 
from spermatogonial proliferation to sperm formation (Miura and Miura, 2003) 
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as well as the quantity of milt produced (Yamazaki and Donaldson, 1969). It 
has been shown to activate Sertoli cells to stimulate production of a 
spermatogonial proliferator, although exact mechanisms of actions are not fully 
identified (Todo et al, 1999). It is thought that this action is mediated by factors 
produced by Sertoli cells in which the androgen receptor exists (Ikeuchi et al, 
2001). 
Progesterones 
In mammals, progesterone is mainly produced by the ovaries, with minor 
secretions by the testes and adrenal glands - it is primarily responsible for 
maintenance of the placenta during pregnancy. In teleost fish, progesterone is 
of little consequence, but from this other progesterones are synthesised (e. g. 
17a, 20ß-dihydroxy-4-pregnen-3-one), and these are involved in the final stages 
of maturation of the oocyte and instigate germinal vesicle breakdown prior to 
spawning (Yoshikuni and Nagahama, 1991; Kime, et al, 1993). 
Plasma steroid concentrations are ultimately a combination of the rate of 
gonadal secretion and rate of hepatic deactivation and excretion. Low plasma 
steroid concentrations could be the result of either inhibited synthesis or 
elevated hepatic catabolism. A wide range of pollutants can stimulate hepatic 
mixed function oxidase (MFO) activity, which is involved in steroid catabolism. 
Such elevated activity could result in more rapid oxidation if the enzyme was 
available for steroid catabolism, but might equally well decrease metabolism if 
the pollutant was preferentially used as substrate (Kime, 1999). 
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1.7.3 Vitellogenin (VTG) 
Vitellogenin is a VHDL (phospholipoglycoprotein), and is the precursor of 
the major egg-yolk proteins of oviparous organisms (Mouchel, 1996). In 
maturing female teleost fish, VTG is the dominant blood protein that is under 
oestrogen control. It is secreted by the liver into the blood stream, and taken up 
by oocytes via receptor-mediated endocytosis. VTG comprises primarily 
precursors of the yolk proteins (lipovitellin and phosvitin), but it also contains a 
proportion of lipid (--20%) (Babin and Vernier, 1989). 
Vitellogenesis is the process by which yolky eggs are produced; it entails 
both the synthesis of vitellogenin by the liver and its uptake by growing oocytes, 
where it is stored as yolk to serve subsequently as the food reserve of the 
developing embryos (Tyler and Sumpter, 1996). The plasma vitellogenin 
concentration rises steadily during sexual maturation of a female fish, 
simultaneously with increasing 17p-oestradiol concentrations (Scott and 
Sumpter, 1983), to reach tens of milligrams per millilitre in some species, at 
which point vitellogenin is the major blood protein. Such high concentrations 
are required by the female to grow an ovary that will contain thousands of large 
yolky oocytes. The plasma vitellogenin concentration consequently increases 
around one million-fold during the seasonal reproductive cycle. 
Vitellogenin has been widely used as a biomarker in the detection of 
oestrogenicity of environmental contaminants in fish (Mouchel et a/ 1996; Orn et 
al 2003; Van den Belt, 2003), and also as an indicator of the oestrogenic activity 
of effluents and the aquatic environment (Purdom et al, 1994; Harries et al, 
1997; 1999). 
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1.7.4 Gamete production 
Normal development of the gametes requires a specific temporal pattern 
of hormone secretion, which is determined by signalling from the gonad itself to 
the pituitary. Such signalling may be of particular importance in indicating that 
the gamete has reached a sufficient stage of maturity for the synthetic pathway 
to switch from 11 KT/estradiol to progesterones. In the ovary, oestradiol 
synthesis must be sufficient to induce the liver to produce vitellogenin which can 
be incorporated into the oocyte. Decreased oestradiol may result in either 
decreased number of eggs, or the normal number of smaller eggs (Tyler et al 
1996). Both of these factors may affect the production of potential viable 
offspring. 
1.7.4.1 Sperm 
The specific cues for controlling the process of spermatogenesis are 
modulated by the endocrine system which have been previously well 
documented by Scott and Sumpter, (1989) and Schulz and Miura, (2002). 
Androgens and FSH are the most important reproductive hormones with 
regards to its regulation (Schulz and Miura, 2002). 
Spermatogenesis is a developmental process with a mitotic, a meiotic, 
and a spermiogenic phase (Schulz et al 2001), which takes place within the 
testicular lobules. The undifferentiated germ cells, which are termed 
spermatogonia, begin to divide mitotically at the onset of gonadal 
recrudescence. The daughter cells of this first division then divide, and so on, 
for a specified number of division cycles, so that a clone of spermatogonia is 
produced from each original spermatogonium. Some differentiation occurs as 
well as mitosis. The cells that result from the final mitotic division and 
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differentiation in the series are called primary spermatocytes, and these are the 
cells that will undergo the first meiotic division of spermatogenesis. 
Not every spermatogonium becomes a primary spermatocyte. At an 
early point, one of the cells of each clone 'drops out' of the mitosis- 
differentiation cycle and reverts to being a primitive spermatogonium that, at a 
later time, will enter into its own full sequence of divisions. In turn, one cell of 
the clone it produces will do likewise, and so on. Thus the supply of 
spermatogonia does not deplete. Each primary spermatocyte changes in size 
and undergoes the first meiotic division to form two spermatids (Grier, 1981; 
Schulz and Miura, 2002). 
The final stage to spermatogenesis is the differentiation of the 
spermatids into mature spermatozoa. This process involves extensive cell 
remodelling, including elongation, but no further cell divisions. In spermatozoa, 
the entire cell is almost exclusively occupied by the nucleus containing the DNA 
that encodes the genetic information (Schulz and Miura, 2002). 
Sperm of teleost fish differs in a number of aspects from those of 
mammals. They are immotile upon ejaculation and only become motile on 
contact with water (Schulz and Miura, 2002, Miura and Miura, 2003). They only 
remain motile for a few minutes at most and enter the egg via the micropyle 
rather than through an acrosomal reaction (Kime, 1999). The first minute after 
induction of motility is therefore crucial for it to succeed in fertilising an egg 
(Kime, 1999). 
1.7.4.2 Eggs 
Fish populations, both fanned and wild, are dependant on the production 
of good quality eggs. Egg quality can be measured by mortality and fertilisation 
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rates, time to hatch, and the proportions reaching the 'eyed' stage and first 
feeding (Bromage, et a/ 1992). Although these give ultimate measures of egg 
quality, they provide no information on the factors affecting egg quality. The 
factors which can affect quality are determined by the intrinsic properties of the 
egg itself, and the environment in which the egg is fertilised and subsequently 
incubated. Once ovulated, fish eggs take up very little, if any, nutrients: only 
water, and chemicals in the water, are known to pass into an ovulated egg 
(reviewed in Brooks et al, 1997) 
In females, LH and FSH are involved in controlling ovarian functions. LH 
stimulates the theca cells of the oocyte to produce androgens, which the 
adjacent granulosa cells, under stimulation of FSH, use to proliferate and 
convert into oestradiol, which is excreted. Oestradiol levels then rise and 
provide positive feedback, leading to an LH surge and ovulation. 
Also crucial to successful oocyte development is the production of the 
Zona radiata proteins (Zrp), fish vitelline envelope proteins, which assist in the 
development of the eggshell. This provides protection for the developing 
embryo against mechanical disturbances during the first fragile period. The 
vitelline envelope is composed of a small number of proteins, which are usually 
synthesised in the teleost liver in response to an oestrogen signal (Arukwe et al, 
1997). Some teleosts however, synthesise these proteins in the ovary itself. 
These glycoproteins are termed ZP1, ZP2 and ZP3, and have molecular 
masses around 200,120 and 80kDa, respectively. Transcription of the ZP3 
gene takes place in the ovary and begins in early oogenesis in female fish; very 
little, if any, Zrp can be detected in male or juvenile fish. The eggshell is shed 
when hatching is induced by developmental and environmental signals. Small 
changes in Zrp synthesis may cause the thickness and mechanical strength of 
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the eggshell to be altered, thus causing a loss in its ability to protect against 
mechanical disturbances during development (Arukwe et al, 1997). 
There is considerable evidence that fish oocytes are particularly sensitive 
to environmental pollutants and that their quality can be adversely affected by 
them (Brooks et al, 1997). For example, fish have a 100-fold greater sensitivity 
compared with mammals to induction of specific mutations during oogenesis 
(Walker and Streisinger, 1983). Malformations and impaired development and 
viability have been shown to result from exposure to a variety of environmental 
contaminants including insecticides, organochiorinated biphenyls and 
polychlorinated biphenyls (Brooks et al, 1997). Exposure may occur when the 
oocytes are developing in the ovary or subsequently when the eggs are 
released into the aquatic environment. Lipophilic chemicals particularly may be 
transported with lipid reserves into the developing oocyte, leading to increased 
rates of mortality and deformities (Knickmeyer and Steinhart, 1989; Miller and 
Amrhein, 1995). 
Pollutants can affect sperm and egg development indirectly via 
disturbance of the correct hormonal environment, but if such pollutants have 
hormonal activity themselves, they can also directly affect the local hormonal 
environment in which the gamete develops. Many chemicals that are described 
as having oestrogenic or other hormonal activity may, like non-hormonal 
chemicals, also have toxic effects. These toxic effects can disrupt gamete 
development both indirectly through toxicity to the endocrine system, or directly 
through toxicity to the gametes themselves (Kime, 1999). The key point about 
any environmental toxicant is that it can have an effect which disrupts 
reproduction at levels below that which disrupt the general health of the fish - 
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consequently the fish is able to live a normal life, but has decreased fertility, for 
example. 
1.8 Previous relevant research 
Clearly, when pharmaceuticals are present in the environment, the 
organisms that live in the aquatic environment will be particularly vulnerable. 
Fish have the potential to take up toxins via several pathways, and these toxins 
may in turn be subject to bioconcentration by virtue of the fact that the fish may 
be permanently surrounded by the contaminated water. Water passes over the 
gills, which are extremely efficient at removing chemicals from the water. These 
chemicals would then enter the blood stream and reach most organs before 
passing through the liver, where they may be metabolised. Also, as many 
species of fish are relatively near the top of the food chain, there is a high 
chance of them receiving exposure via eating contaminated food (the chemicals 
may be found at high concentrations in them due to biomagnification). 
Concentrations of pharmaceuticals found in the environment are in the 
ng/I range, or occasionally low pg/I, and this is at least 3 to 4 orders of 
magnitude lower than those producing a pharmacological effect in humans. The 
levels presently found in the environment are therefore not considered to be 
significant when compared to therapeutic doses in humans, although they must 
be considered further with regard to subtle long term or chronic effects of 
lifetime exposure within the aquatic environment. 
To date, there are only a handful of studies which have reported on the 
effects of clofibrate or clofibric acid on fish. In 1998, Perkins and Schlenk 
exposed catfish to 0,10,50,100 and 225mg clofibric acid per litre, for 24hrs in 
a static tank water system. They showed that treatment with water-borne 
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clofibric acid caused a dose-dependant increase in the 51-kDa CYP2 protein 
and also a dose-dependant increase (although not significant) in HSI. The 
highest concentration (225mg/I) caused death and 100mg/I caused 
haemorrhaging to the tail and pectoral fins. Concentrations of 10 and 50 mg/I 
caused dose response but over those concentrations effects decreased to 
those similar to the controls. 
Pretti et al (1999), looked at the effect of 35 or 70mg/kg Clofibrate on 
enzymes in liver, kidney and gill of 4-year-old sea bass after 2 weeks daily IP 
injection. They also found no significant changes in cytosolic, microsomal, 
mitochondrial or peroxisomal enzyme activities compared to the controls. They 
did, however, find induction of hepatic glutathione S-transferase activity. They 
concluded that adult sea bass are essentially refractory to a classical 
peroxisome proliferator such as Clofibrate. In trout, salmon and medaka 
hepatocytes, however, the induction of peroxisome proliferator marker enzymes 
in response to clofibrate has been observed (Yang et al, 1990, Scarano et al, 
1994, Donohue et al, 1993, Ruyter et al, 1997). These support conclusions 
found in mammalian models. 
Haasch (1998), exposed male blue gill to clofibrate via IP injection and 
found significant cytochrome p450 induction. In 2004, Kazeto et al looked at 
endocrine effects of clofibrate on juvenile zebrafish, including at the levels of 
expression of the CYP19 genes - the key steroidogenic enzyme responsible for 
the conversion of androgens to oestrogens. They found no significant changes 
in expression of the CYP19 genes after exposure to clofibrate, however there 
was a tendency for a decrease in abundance by 60-70% in some cases (so a 
possible trend). When they exposed zebrafish to EE2 and clofibrate together, 
they found that there was no anti-oestrogenic effect. They concluded that there 
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were no oestrogenic effects and no anti-oestrogenic effects at concentrations of 
Clofibrate of 0.01-10pM during 3 days of exposure. They also exposed adult 
zebrafish to clofibrate at the same concentration and determined that it was 
effective in inducing a PPAR gene response after 3 days exposure. 
1.9 Aims of the PhD 
This project is concerned with the presence of pharmaceutical drugs, in 
particular clofibric acid, in the aquatic environment and their effects on fish. The 
aim is to investigate the effects of these drugs on fish at environmentally 
relevant concentrations, in order to determine whether the amounts of these 
drugs in the environment are great enough to cause a deleterious effect at the 
individual or whole population level in fish. 
There is a plethora of information which has recently been disseminated 
in the scientific press regarding levels of pharmaceutical drugs (and their 
metabolites) identified in the aquatic environment. Very little information, 
however, is available for pharmaceutical exposure, and any consequent effects 
in aquatic organisms. 
The aims of this thesis are: 
" To summarise the data available on occurrence and detection of 
pharmaceuticals. 
" Determine if effects on fish occur, using an open ended and varied 
approach, beginning with a number of preliminary experiments to guide 
subsequent experiments. These involved assessing possible effects, on 
both embryos and adult fish, and investigating parameters ranging from 
physiological and biochemical ones, through to effects at the molecular 
level. 
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Chapter 2: Material and Methods: 
Methods employed in determining the effects of a 
pharmaceutical drug metabolite, clofibric acid, on fish. 
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As so little is known about the effects of pharmaceutical drugs on fish, 
the methods employed to determine if any effects occur must be diverse and 
take into account the effects that occur in humans taking the drug. However, 
just because a drug has a specific mode of action in humans, it may not act in 
the same way in a different organism. It may cause novel adverse reactions in 
normal functions in other organisms, possibly even at concentrations lower than 
those normally applied to humans. Deciding on which particular endpoints to 
employ for the research reported in this thesis was therefore very difficult. 
2.1 Dosing Experiments 
It was decided that in vivo studies would be the best approach for 
detecting pharmaceutical effects in fish, because this approach might enable us 
to identify whole body effects. The basic methodology employed is included 
below. In subsequent chapters, the specific details relevant to the particular 
experiments reported in that chapter are provided. 
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II PHARMACEUTICALS IN THE ENVIRONMENT 11 
Embryo Exposure 
CHAPTER 3 
Embryos exposed from l hr 
post fertilisation through to 
hatch -3 different 
concentrations clofibric acid 
Bream Exposure 
CHAPTER 4 
Experiment 1- 21 day, flow 
through exposure to 1 mg/I 
clofibric acid 
Fathead minnow Exposures 
CHAPTER 5 
Experiment 2 
7 day, static 
exposure to 
Img/I clofibric 
acid 
4 experiments using adult fathead 
minnow exposed to different 
concentrations of clofibric acid 
Experiment 3 
21 day, flow 
through 
exposure to 
1 mg/I clofibric 
acid 
(Worms 
present) 
Experiment 4 
Repeat 21 day, 
flow through 
exposure to 
1 mg/I clofibric 
acid 
Experiment 5 
21 day, flow 
through 
exposure to 
10µg/I and 
1 mg/I clofibric 
acid 
Molecular Aspects 
CHAPTER 6 
Possible effects of clofibric acid on 
gene expression 
Figure z. 1: structure of the research reported in this thesis - An overview 
of experiments carried out using Clofibric acid. 
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2.1.1 Test Organisms 
Two species of fish were used for all the exposure experiments, the 
Bream (Abramis brama) for the preliminary adult study (Chapter 4) and the 
fathead minnow (Pimephales promelas) for the embryo study (Chapter 3) and 
for subsequent adult experiments (Chapters 5 and 6). Initially, the Bream was 
chosen for the adult experiment because individuals of this species are large 
(larger than the fathead minnow), and consequently blood could be taken pre 
and post exposure from the same fish, thus enabling within-fish data analysis to 
be conducted. 
The Bream (Abramis brama) 
The common bream (Abramis brama) is a common cyprinid fish that lives 
in large numbers in the lower reaches of slow flowing, large rivers, lowland 
reservoirs and lakes. It has a high, laterally flattened body with a lead blue back 
and silvery sides. They can grow to a length of 30cm, a weight of 6kg, reach 
sexual maturity at 2+ years, and can live naturally for up to 25 years. 
The fathead minnow (Pimephales promelas) 
The fathead minnow (Pimephales promelas) is a representative of the 
ecologically important and ubiquitous Cyprinidae family. It has been extensively 
used in chronic life cycle and early life stage survival and development tests in 
support of regulatory programs, both in Europe and North America (Jensen et 
al, 2001). It is a small freshwater fish, with adults reaching an average length of 
50mm and a weight of 5g. Sexually mature males have a striking appearance, 
and are easily distinguished from the females - they are larger and darker in 
colour with vertical bands on the body and head (Figure 2.2). They also have 
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tubercles on the face and a prominent fatpad on the top of the head (hence the 
name fathead). In contrast, the female is silvery/olive in colour, and has a more 
pointed head. She has an ovipositor and a swollen ventral contour associated 
with the presence of mature eggs. 
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Figure 2.2: Photograph of the adult male and female fathead minnow 
(Pimephales promelas). 
Under optimal conditions, the fathead minnow reaches sexual maturity at 
about 4-5 months post hatch. They are fractional spawners and under 
favourable conditions the females can produce clutches of 50-100 eggs every 3 
to 5 days (Harries et al, 2000). The incubation period is about 4 days at 25°C, 
after which newly hatched fry of about 5mm in length hatch out. 
The fathead minnow is relatively easy to culture in a laboratory setting 
using standard methods (EPA, 1987), and control of its reproduction cycle is 
readily achieved through alterations in temperature and photoperiod. 
A continuous flow-though system (Figure 2.3) was employed for all 
except one (Experiment 2) of the exposure experiments, using 30 litre glass 
tanks, ensuring a complete water change of dechlorinated tap water (5 and 
10pm carbon filtered) every 3hrs. Parameters monitored within the test tanks 
throughout the studies were: temp (25±1 °C) and dissolved oxygen level 
(8±1 mg/I), and the photoperiod was maintained at 16h light: 8hr dark 
throughout, incorporating 20 min dawn: dusk transition periods. 
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Figure 2.3: The dosing set up used to expose fish to Clofibric acid. 
2.1.2 Preparation of stock solutions and dosing of tanks 
Stock solutions of clofibric acid were freshly prepared in 4 litre amber 
bottles prior to each experiment. Clofibric acid (CAS No: 882-09-7, purity >97%) 
was dissolved in double distilled water by stirring vigorously overnight and 
heating gently (to - 40°C). The stock solution (see individual chapters for 
nominal tank concentrations) was dosed at 12ml/hr (0.2ml/min), using a Watson 
Marlow (Cornwall, UK) Multi channel, peristaltic pump, into glass mixing vessels 
(aspirator bottles), where it mixed with dilution water (at 101/hr) before delivery 
to each of the test tanks. All tubing within the system was medical grade 
silicon. The chemical was left dosing for a week prior to fish being put into the 
tanks, to allow the system to equilibrate. For numbers and sex of fish per 
exposure experiments, see details of individual experiments in subsequent 
chapters. Flow rate and stock solution dosing were monitored daily. 
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2.1.3 Sampling fish 
At the end of each experiment (apart from bream exposure - see Chapter 
4), fish were anaesthetised using MS-222 (Sigma, Poole, UK) at 40-100ppm to 
obtain complete anaesthesia (Ostrander, 2000), blood sampled and killed using 
standard procedures approved by the UK Home Office. 
Blood Sample collection and storage from fathead minnow 
For lipoprotein analysis, blood was collected via a tail cut (through the 
caudal peduncle), into 75pl capillary tubes (with no heparinthen decanted into 
eppendorf tubes and kept on ice. The blood samples were then left to 
coagulate, after which they were spun in a centrifuge at 12,000x g for about 15 
seconds. Serum was then taken off carefully and stored at 4°C (for a maximum 
of three days) before lipoprotein assays were carried out (Section 2.2.2). 
Plasma samples for analysis of triglyceride, cholesterol, sex steroid and 
VTG levels were collected similarly, although the capillary tubes used to collect 
the blood contained heparin and the eppendorf tubes contained the enzyme 
inhibitor aprotinin (Sigma). Blood samples were kept on ice until plasma was 
separated by centrifugation for 4 minutes at 14,000x g, and this was then stored 
at -20°C ready for analysis (see Sections 2.2.3,2.2.4 and 2.2.5). 
Blood Sample collection and storage from bream 
Blood samples from bream for lipoprotein analysis (Chapter 4) were 
taken using a 5ml syringe and needle. Blood samples were kept on ice until 
they coagulated and then briefly spun at 12,000x g for 15 seconds. Serum was 
Heparin must not be used during collection of blood for lipoprotein analysis as it alters the lipoprotein 
profile (Wayne Brown, Hillingdon Hospital, Personal Communication, 2001). 
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then taken off carefully and stored at. 4°C (for a maximum of three days) before 
lipoprotein assays were carried out (Section 2.2.2). 
Plasma samples for analysis of triglyceride, cholesterol, and VTG levels 
were collected similarly, although the syringes used to collect the blood 
contained heparin and the eppendorf tubes contained aprotinin (Sigma). Blood 
samples were kept on ice until plasma was separated by centrifugation for 4 
minutes at 14,000x g, and this was then stored at -20°C ready for analysis (see 
Sections 2.2.3,2.2.4 and 2.2.5). 
2.1.4 Dissection of fish 
After blood was taken, the fish were measured (fork length, in 
millimetres) and weighed (grams) and, depending on the experiment, gonad 
and liver were either removed and weighed using RNase free conditions, snap- 
frozen in liquid nitrogen and stored at -80°C until needed for analysis or, if the 
testis was being used for determination of sperm count, it was not snap-frozen. 
The gonadosomatic index (GSI) expresses the size of the gonad in 
relation to the body weight. It was calculated by using the following formula: 
GSI = gonad wt (g)/body wt (g) x 100 
The hepatosomatic index (HSI) expresses the size of the liver in 
relation to the body weight. It was calculated by using the following equation: 
HSI = liver wt (g)/body wt (g) x 100 
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2.2 Endpoint Methods 
2.2.1 Sperm count 
Sperm counts were not initially considered as an endpoint for the 
exposure experiments, but were carried out as a pilot study in Experiment 4. 
When interesting results were obtained, it was decided that for the final 
exposure experiment (Experiment 5), it should be an endpoint. Sperm counts 
were determined using an established method (Katrien VanLook, personal 
communication; 2003; WHO, 1992). Testes were removed from the fish and 
weighed, and a known amount was then placed into an eppendorf tube (Alpha 
Labs, Hampshire) with 200pl catfish extender (pH 7.58, NaCl 94mM 5.52g/I, 
KCL 27mM 200g/l, Tris HCL 15mM 2.42g/I, Glycine 50mM 3.75g/l, made in 
nanopure water. These samples were then immediately stored at 4°C until 
analysed (within 1 week of sampling). 
The testis was homogenised thoroughly, using a clean pipette tip, and 
1 pl of the homogenate was then added to 99pl of trypan blue and left in a `damp 
box' for 10 minutes. Counting of mature viable (Figures 2.4 a and b) and non- 
viable sperm was carried out using a Neubauer haemocytometer (Weber, UK) 
(depth 0.1 mm) containing 2Opl of the sample, under x40 magnification. Viable 
sperm were identified by their movement and their ability to exclude the trypan 
blue, whereas dead sperm were identified by their uptake of the trypan blue and 
non-movement. 
Cell counting rules were used as follows: 
9 In the first grid, if <10 mature sperm - count all 25 squares 
" If 10-40 mature sperm, count 10 random squares 
" If >40 mature sperm, count 5 random squares 
58 
These results were then analysed taking into account gonad weight, and the 
number of sperm per mg gonad was calculated. 
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Figure 2.4: a) Mature sperm (picture kindly supplied by Krishen Rana, 
University of Stirling) and b) sperm on a haemocytometer. 
2.2.2 Measurement of Cholesterol within Lipoproteins 
Traditionally, lipoproteins were separated by ultracentrifugation, and in 
fish this approach has been carried out on a number of species, including 
Rainbow trout, Pacific sardines, and Catfish (Babin, 1989). More recently, a 
method involving separation according to their electrophoretic properties has 
been used. This is based on their electrophoretic migration on agarose gels 
(e. g. Babin, 1989; Santulli et al, 1989). 
a- Lipoproteins - HDL 
C7 I Pre -0- lipoproteins - VLDL 
®1 lipoproteins - LDL 
Origin (application point) 
Figure 2.5: Separation of plasma lipoproteins by electrophoresis on 
agarose gel (adapted from Murray et al, 1993). 
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Serum was analysed using a method based on the HYDRAGEL 
LDL/HDL CHOL direct kit (Sebia, France). This kit is routinely used in clinical 
biochemistry labs for the quantification of cholesterol within lipoproteins in 
human serum, and involves electrophoresis on alkaline-buffered (pH 9.1) 
agarose gels. The system works by assaying for the cholesterol content of the 
high-density lipoproteins (HDL) low-density lipoproteins (LDL) and very low- 
density lipoproteins (VLDL). The process is carried out in two stages; firstly, 
electrophoresis on agarose gel is used to separate the VLDL, LDL and HDL, 
followed by visualization of the cholesterol within each of the lipoprotein 
fractions using a sensitive and cholesterol-specific enzymatic method, based on 
the following reactions: 
cholesterol ester + H2O 
Cholesterol esterase free cholesterol + fatty acids 
free cholesterol + NAD 
Cholesterol dehydrogenase 
cholestenone + NADH + H+ 
NADH + PMS 14 lo reduced PMS + NAD 
Reduced PMS + NBT PMS + reduced NBT 
Precipitate of formazan (blue) 
These stained gels can be evaluated by densitometry to obtain relative 
quantification of individual zones (bands). The amount of resulting formazan 
precipitate is proportional to the cholesterol concentration. The assay has been 
shown previously to have good sensitivity and to be linear in the entire range 
studied. 
Serum samples (previously stored at 4°C and used within 3 days) were 
applied (6pl of serum + 4pl buffer) to the gel (agarose, 0.8g/dL; alkaline buffer, 
pH 9.1) via an applicator and left for 15 minutes. Six serum samples were run 
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These results were then analysed taking into account gonad weight, and the 
number of sperm per mg gonad was calculated. 
Figure 2.4: a) Mature sperm (picture kindly supplied by Krishen Rana, 
University of Stirling) and b) sperm on a haemocytometer. 
2.2.2 Measurement of Cholesterol within Lipoproteins 
Traditionally, lipoproteins were separated by ultracentrifugation, and in 
fish this approach has been carried out on a number of species, including 
Rainbow trout, Pacific sardines, and Catfish (Babin, 1989). More recently, a 
method involving separation according to their electrophoretic properties has 
been used. This is based on their electrophoretic migration on agarose gels 
(e. g. Babin, 1989; Santulli et al, 1989). 
Lipoproteins - HDL 
Pre -ß- lipoproteins - VLDL 
p- lipoproteins - LDL 
Origin (application point) 
Figure 2.5: Separation of plasma lipoproteins by electrophoresis on 
agarose gel (adapted from Murray et al, 1993). 
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Serum was analysed using a method based on the HYDRAGEL 
LDUHDL CHOL direct kit (Sebia, France). This kit is routinely used in clinical 
biochemistry labs for the quantification of cholesterol within lipoproteins in 
human serum, and involves electrophoresis on alkaline-buffered (pH 9.1) 
agarose gels. The system works by assaying for the cholesterol content of the 
high-density lipoproteins (HDL) low-density lipoproteins (LDL) and very low- 
density lipoproteins (VLDL). The process is carried out in two stages; firstly, 
electrophoresis on agarose gel is used to separate the VLDL, LDL and HDL, 
followed by visualization of the cholesterol within each of the lipoprotein 
fractions using a sensitive and cholesterol-specific enzymatic method, based on 
the following reactions: 
cholesterol ester + H2O 
Cholesterol esterase free cholesterol + fatty acids 
free cholesterol + NAD 
Cholesterol dehydrogenase 
cholestenone + NADH + H'' 
NADH + PMS 4 lo reduced PMS + NAD 
Reduced PMS + NBT PMS + reduced NBT 
Precipitate of formazan (blue) 
These stained gels can be evaluated by densitometry to obtain relative 
quantification of individual zones (bands). The amount of resulting formazan 
precipitate is proportional to the cholesterol concentration. The assay has been 
shown previously to have good sensitivity and to be linear in the entire range 
studied. 
Serum samples (previously stored at 4°C and used within 3 days) were 
applied (6pl of serum + 4pl buffer) to the gel (agarose, 0.8g/dL; alkaline buffer, 
pH 9.1) via an applicator and left for 15 minutes. Six serum samples were run 
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on each gel, plus one standard which was run on all gels. The gel was then 
placed carefully into an electrophoresis chamber using the following conditions: 
150ml tris-barbital buffer (2.45% barbital, 13.73% sodium barbital, 0.13% 
sodium azide) pH 9.2) per compartment (300ml total), initial current (per gel) of 
10±2 mA, and a constant voltage of 60V. 
After running the gel for one hour, visualisation solution (2ml NaCl; 
added to the enzyme vial supplied with the kits, which contained cholesterol 
esterase, cholesterol dehydrogenase, nicotinamide adenine dinucleotide and 
0.5ml chromogen (nitroblue tetrazolium and phenazine methosuiphate)) was 
added to the surface of the gel using an applicator and the gel left for 30 
minutes at room temperature. The solution was removed, a blocking solution 
was added and the gel was then left for 10 minutes at room temp. Filter paper 
was applied on top of the gel and it was placed in an incubator for 15 minutes at 
51 °C. The gel was subsequently submerged in destaining solution for 20 
minutes, then removed and completely dried at 51 °C. 
The resulting gels were scanned using an Alpha Imager 1220 and 
analysis system V5.5. It was set up using filter 2, white light table, white 
transilluminator and reflective white light, and an image was obtained (Section 
5.2.1). Densitometry was then carried out on these images and the intensity of 
each band was calculated using the area-under-the-curve function in the 
analysis software (Figure 5.2 in Chapter 5). These results were then analysed, 
comparing control and exposed fish, after standardising each area to the 
internal standard. 
61 
ýf-HDL 
-f-LDL 
f-Application point 
4 -HDL 
f-VLDL 
-f-LDL 
fApplication point 
Figure 2.6: Migration patterns for human lipoproteins on Sebia gels. 
Depending on the sample composition, either one of two patterns can be 
observed. In fish however, HDL dominates within the plasma (Babin and 
Vernier, 1989), and consequently the top band is the main one visualised. In 
contrast, when human serum was run as a standard, LDL is the main band. 
2.2.3 Manual methods for measurement of cholesterol and 
triglyceride levels. 
Enzymatic methods were used to quantify both cholesterol and 
triglyceride levels in the serum sample obtained from some of the experiments. 
Plasma levels of triglyceride and total cholesterol were measured using a 
colorimetric assay kit purchased from ThermoTrace DMA (Victoria, Australia). 
Reagent volumes were modified from those used with human plasma, using a 
method adapted by Jensen (2002) to accommodate the small volumes of 
plasma collected from small fish and the lipid-rich nature of the plasma. 
All assays were performed in non-absorbent Titertek 96-multiwell flat- 
bottomed plates (Flow labs, Irvine). For the standards, 35pl 0.9% saline was 
added to each well, followed by 15pl of each standard. Sample wells received 
49pl of 0.9% saline followed by 1 pl plasma, and blanks contained 50pI of 0.9% 
saline. 
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Cholesterol Assay 
A non-absorbent 96 well plate (Titertek, Flow labs, Irvine) was prepared, 
containing blanks (50pl 0.9% saline), cholesterol standards (Sigma C0534), (an 
example is shown in Figure 2.7), at 0.03,0.06,0.09,0.12,0.15,0.18,0.24 and 
0.3 pg/pl made up to 5Opl with 35pl 0.9% saline, and samples (1 pl serum plus 
49NI 0.9% saline). The plate reader (Molecular Devices, Spectra Max 340pc) 
was turned on prior to preparation of the plate to ensure 37°C had been 
reached. 15Opl of cholesterol reagent (liquid stable - cholesterol oxidase, 
cholesterol esterase, peroxidase (horseradish), 4-aminoantipyrine, HBA, buffer 
and surfactants - pH 6.7±0.1 at 20°C) was then added to all wells, and the plate 
shaken and incubated in the plate reader at 37°C for 5 minutes. Just before 
reading, the plate was again shaken, and it was then read at an absorbance of 
500nm. Calculations were carried out using SOFTmaxPRO version 3.0 (which 
used the regression equation from the standard curve) to determine actual 
concentrations in the samples. 
..,,,, 
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3 Cholesterol 
standard 
curves run in 
duplicate 
Figure 2.7: An example of a 96-well plate used for the manual cholesterol 
assay - showing three cholesterol standard curves (at different dilutions) 
which were all run in duplicate. 
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The reactions involved in the assay are as follows: 
CE 
1. Cholesterol esters 10 Cholesterol + fatty acids 
co, 
2. Cholesterol + 02 
POD 
3.2H202+ HBA + 4AAP 10 
Cholest-4-en-3-one + H202 
Quinoneimine Dye + 4H20 
Where: CE = cholesterol esterase, CO = Cholesterol oxidase, HBA= 
Hydroxybenzoic acid, 4AAP = 4-aminoantipyrine, POD = Peroxidase. 
y=1.7016x + 
0.6 
0.5 
0.4 
0 0 
cc 
0.3 
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0 
0.35 
Figure 2.8: An example of a typical standard curve produced for the 
cholesterol assay. The cholesterol level of the unknown sample can be 
determined by reading the cholesterol concentration that corresponds to the 
absorbance value of that unknown. 
Triglyceride Assay 
As with the cholesterol assay, a non-absorbent 96 well plate (Titertek, 
Flow labs, Irvine) was prepared as described previously, containing blanks (50pl 
0.9% saline), triglyceride standards (Sigma) at 0.03,0.06,0.12,0.15,0.18,0.24 
and 0.3 pg/pI made up to 5Opl with 35pl 0.9% saline, and samples (1 pI serum 
plus 49pi 0.9% saline). The plate reader (Molecular Devices, Spectra Max 
340pc) was turned on prior to preparation of the plate to ensure 37°C had been 
reached. 150NI of triglyceride reagent (liquid stable; ATP 2.5mmol/l, Mg2+ 
2.5mmol/I, 4-Aminoantipyrine 0.4mmol/I, 4-Chiorophenol 2mmol/I, Peroxidase 
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0 0.05 0.1 0.15 0.2 0.25 0.3 
Concentration (mg/ml) 
(Horseradish) >2000U/I, GK (microbial)>6000/I, GPO (Microbial) >6000U/I, 
Lipoprotein lipase (microbial) >3000U/I, Buffer 55mmol/I at pH 7.3±0.1 at 20°C) 
was then added to all wells, shaken and incubated in the plate reader at 37°C 
for 5 minutes. Just before reading, the plate was again shaken, and it was then 
read at an absorbance of 500nm. Calculations were carried out using 
SOFTmaxPRO version 3.0 (which used the regression equation from the 
standard curve) to determine actual concentrations in the samples. 
The reactions involved in the assay are as follows: 
lipase 
1. Triglycerides + H2O 10 Glycerol + Free fatty acids 
GK 
2. Glycerol + ATP o Glycerol-3-phosphate + ADP 
GPO 
3. Glycerol-3-phospate + 02 No DAP + H202 
Peroxidase 
4. H202 + 4-AAP + 4-CP , Quinoneimine dye + 2H20 
Where: ATP - Adenosine triphosphate, GK - Glycerol kinase, ADP - Adenosine diphosphate, DAP - Dihydroxyacetone phosphate, 4AAP-4-aminoantipyrine, 
4CP - 4-chlorophenol. 
Standard curve for triglycerides 
0.6 
0.5 
0 0.4 
0 
m 0.3 
U) 
2 0.2 
0.1 
0 
y=1.4931x + 0.0736, 
R2 = 0.9958 
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 
Concentration (mg/ml) 
Figure 2.9: An example of a typical standard curve for the triglyceride 
assay. The triglyceride level of the unknown sample can be determined by 
reading the triglyceride concentration that corresponds to the absorbance value of that unknown. 
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2.2.4 Vitellogenin ELISA 
The VTG Enzyme-Linked-Immunosorbant-Assay (ELISA) based on carp 
vitellogenin (Cyprinus carpio), previously validated for use in a wide range of 
other species by Tyler et al, (1996) was used (see Chapter 4) to determine 
concentrations of vitellogenin present in the plasma of bream before and after 
exposure to clofibric acid. The protocol was as follows: - 
Day 1: A VTG (carp-VTG) standard curve was prepared in duplicate in a 
non-absorbent Titertek 96-multiwell flat-bottomed plate (Flow labs, Irvine), with 
a two-fold serial dilution ranging from 500 to 0.03 ng/ml ('Plate 1'). Unknown 
plasma samples were assayed in duplicate, by adding 60pl plasma to each well. 
6Opl of blocking buffer (0.01M sodium phosphate, 0.9% sodium chloride, 0.05% 
tween, 1% bovine albumin, pH 7.4) was added to the well for the maximum and 
non-specific binding levels. 60pl of the carp vitellogenin antibody (1: 50 000) 
was added to each well and the plate was covered with microplate sealing film 
(Anachem, Bedfordshire). In parallel, wells in an immunsorbant plate -'plate 2' 
(NuncTM maxisorp microtitre plate, GibcoBRL) - were coated with 60 ng of carp- 
VTG (in 100pl), except for those used to determine non-specific binding, to 
which 100pl of coating buffer (0.05M sodium bicarbonate, pH 9.6) was added. 
Both plates were incubated at 4°C overnight. 
Day 2: On the following day, plate 2 (immuno plate) was washed three 
times with wash buffer (0.01 M sodium phosphate, 0.9% sodium chloride, 
0.05% Tween, pH7.4) to remove any unbound VTG. Subsequently, 150pl of 
blocking buffer was added to each well. The plate was then incubated at 37°C 
for 30 minutes, together with plate 1, containing the standards and unknown 
samples. Following the incubation, plate 2 was washed as before and 100pi of 
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standard/samples were taken from each well on plate 1 and transferred to plate 
2. Plate 1 was then discarded and plate 2 incubated for 60 min at room 
temperature. Plate 2 was then washed, as before, and 125pI of second 
antibody (goat-anti-rabbit horse-radish peroxidase-linked; 1: 2000 dilution; 
Sigma) was added to each well. The plate was then incubated at 37°C for 120 
minutes. Following this, 125pl of substrate buffer (0.05M dibasic sodium 
phosphate, 0.024M citric acid, pH 5.0; and just before use, the addition of 0- 
phenylene diamine (0.05mg/ml) and 0.5p1/mI hydrogen peroxide) was added to 
each well and the plate incubated in the dark at room temperature for 50 min. 
The reaction was stopped by adding 30pl of 3M sulphuric acid to each well. 
The plate was then incubated for a further 10 minutes in the dark and the 
absorbance was read at 450nm using a plate reader (Molecular Devices, 
Spectra Max 340pc). The level of maximum binding was calculated according 
to the formula below: 
Average of duplicate - average of NSB values x 100 
Average maximum binding - non specific binding 
100 
80 
rn60 
c 
40 
20 
o 1---ý 
0.1 1 1000 Concentration (ng/M) 100 
Figure 2.10: An example of a standard curve produced from the 
vitellogenin ELISA. Data from the unknown samples can then be read off the 
standard curve to give the concentration of vitellogenin in ng/ml. 
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The standard curve was plotted (semi logarithmically) (Figure 2.10), by 
plotting percentage binding against VTG concentration. VTG concentrations of 
the unknowns were then read from this (unknown concentrations are generally 
taken from between 20-80% binding, as this is the straightest part of the curve). 
2.2.5 Sex steroid Radioimmunoassays 
Plasma testosterone and 11 -Ketotestosterone concentrations were not 
initially intended as endpoints for any of the experiments within this study, but 
after obtaining the sperm count data it was decided that it would be very 
interesting to determine them (see Section 5.5.4.1 for results). These assays 
were kindly carried out by Miss Susan Maddix. 
The principal of the radioimmunoassay is based upon the equal 
competition between a radiolabelled ligand and an unlabelled ligand for binding 
to a specific antibody. The amount of the radiolabelled ligand and antibody used 
in an assay are kept constant so that, when the mixture of reagents has been 
allowed to equilibrate, the amount of radiolabelled ligand bound to the antibody 
will be dependant on the amount of unlabelled ligand in the mixture. The 
maximum amount of label, or `maximum binding' (MB), is determined by 
incubating the labelled ligand and the antibody alone. Some small amounts of 
label will also act as bound ligand, even when there is no antibody, and this 
amount is known as the non-specific binding (NSB). Reasons for the non- 
specific binding include: binding of label to other assay components, trapping of 
label to the bound complex, impurities in the label, absorption of free tracer to 
the reaction tube, or the incomplete aspiration of the unbound fraction from the 
tube. The values represented by the MB and NSB are in effect the upper and 
lower limits of the assay. Within each assay, a standard curve is included to 
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determine the concentration range over which the amount of unknown ligand 
can be quantified. The assay is set up with fixed amounts of antibody and label 
and serially diluted concentrations of known amounts of unlabelled standard. 
The NSB value is subtracted from the MB value and the corrected MB is taken 
as 100%. The remaining values for the standard tubes are also corrected for 
NSB and are expressed as a percentage of MB. The data are plotted on a 
logarithmic scale and a sigmoidal curve is produced. The central region of the 
curve is where extrapolations of sample counts to sample concentration can be 
made (the straight region in general lies between 20 and 80% of maximum 
binding). 
At the end of the radioimmunoassay, the free unbound label needs to be 
separated from the antibody-ligand complex. In steroid assays, this separation 
involves the use of activated charcoal, to which small molecules will be 
absorbed. Unlabelled ligand will thus be adsorbed and this complex will be 
precipitated out by centrifugation. The antibody (with bound labelled or 
unlabelled hormone attached) remains in the supernatant, which is decanted 
directly into beta scintillation vials and retained for counting. Albumin or dextran 
is used to fill the mesopores of the charcoal, to prevent adsorption of the bound 
antibody-ligand complex into these larger sites. The timings of the reaction and 
temperature of the assay tubes must be kept constant to avoid excessive 
variation between assays. In large assays, NSB and MB tubes were also 
included in each batch of samples within the assay, to allow adjustment for 
batch-to-batch variation. 
The radioactivity, or beta rays, emitted from the samples are measured 
using a scintillation counter. -. These rays are particulate and not highly 
penetrative, so cannot pass through the plastic . tube. To get around this 
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problem, photons of light are generated within the vial, by a liquid scintillate 
which is activated by the radiation. The photons pass through the vials and can 
be detected by photomultipliers with the scintillation counter. 
Testosterone and 11-Ketotestosterone radioimmunoassays were carried 
out using plasma samples obtained from Experiment 5. The samples were 
extracted using ethyl acetate (which separates the steroids from their sex 
steroid binding proteins) prior to the assay using a method modified for use with 
the small amounts of plasma obtained from the fathead minnow. 
Method in detail 
10pi of plasma was transferred to a polypropylene tube, followed by the 
addition of 250pl ethyl acetate. The tube was capped, shaken and stored at - 
20°C. On the day of the assay the samples (plasma plus ethyl acetate) were 
spun at 2500g for 2 minutes to separate the ethyl acetate (top layer) from the 
plasma (lower layer). The ethyl acetate, containing the extracted steroid 
hormones, was decanted into another tube. The ethyl acetate was then 
removed using a gyrovap (Howe, London, UK) and the steroid remaining was 
re-dissolved in 100pl buffer (0.05M phosphate buffered saline (PBS, Oxford), 
gelatine (Sigma), sodium azide). 200pl buffer was added to the total counts and 
NSB tubes; 100pI was added to each standard tube except the first pair. 
Standard was serially diluted from the second to the last standard, along an 
entire row, before serially diluting a duplicate row of standards. 
100pl of labelled (tritiated) hormone (approximately 6000 dpm for both 
testosterone and 11 KT RIAs) was added to each tube. 100NI of antibody 
(diluted 1: 50,000 for both testosterone and 11 KT; kindly supplied by D. Kime of 
Sheffield University), was added to all tubes except the total counts and NSB 
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tubes. Tubes were then vortexed and centrifuged briefly to ensure the contents 
were in the base. The tubes were then covered and incubated overnight at 4°C. 
Day 2: As previously mentioned, activated charcoal was used to separate 
the bound complex from the unbound label led hormone. Dextran-coated 
charcoal was prepared (0.5% activated charcoal; 0.05% dextran in buffer) 15 
minutes prior to use. 500pl buffer was then added to the total count tubes. 
500p1 activated charcoal mixture was added to each of the remaining tubes 
(one batch at a time), the tubes vortexed and incubated on ice for 10 minutes 
prior to centrifuging at 2500g for 15 minutes, at 4°C. The supernatant 
(containing the bound fraction) was removed and transferred to scintillation vials 
to which 4 ml scintillation fluid (Liquiscint, National Diagnostics) was added. 
The tubes were then shaken and counted in a ß-counter for 5-10 minutes. 
Calculations were carried out by hand using mean dpm for each pair of 
tubes and applying the following equation: ((unknown-NSB)/(MB-NSB))xlOO. 
The standard curve was plotted on log-normal paper, and the unknown values 
were read from the linear part of the curve, usually between the 20 and 80% 
binding (Figures 2.11, a and b). The testosterone assay is highly specific and 
sensitive; the detection limit was 0.033ng/ml. The detection limit for the 1 1-KT 
assay on the other hand was 0.28ng/mI. 
71 
100 
80 
cp 60 S v 
c 
co 
° 40 
20--- 
0.1 
0.1 0.001 0.01 concentration (ng/ni) 
1 10 
I- 
t-igure z. i i: i ypicai stanuaru curves rar Ene a) testosterone anu u) 
11-ketotestosterone radioimmunoassay. Where concentrations of T 
and 11-KT in the unknowns can be read from the standard curve by 
extrapolating the percentage binding on the y-axis and reading down to 
the x-axis to give a concentration of ng/ml. 
2.2.6 Yeast oestrogen assay 
Clofibric acid was kindly analysed by David Hala using both the yeast 
oestrogen and androgen screens, using the protocols described by Routledge 
and Sumpter (1996) and Sohoni and Sumpter (1998). These assays are 
commonly utilised for the detection of oestrogen and androgen activity in test 
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Figure 2.11: Typical standard curves for the a) testosterone and b) 
11-ketotestosterone radioimmunoassay. Where concentrations of T 
and 11-KT in the unknowns can be read from the standard curve by 
extrapolating the percentage binding on the y-axis and reading down to 
the x-axis to give a concentration of ng/ml. 
2.2.6 Yeast oestrogen assay 
Clofibric acid was kindly analysed by David Hala using both the yeast 
oestrogen and androgen screens, using the protocols described by Routledge 
and Sumpter (1996) and Sohoni and Sumpter (1998). These assays are 
commonly utilised for the detection of oestrogen and androgen activity in test 
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chemicals. It is a straightforward assay carried out in a 96-well microtitre plate, 
thus allowing a wide range of concentrations of test chemical to be tested in 
each assay. 
Essentially, the human oestrogen receptor (hERa) and androgen 
receptor (hAR) genes have been integrated into the main genome of the yeast. 
The yeast also contains an expression plasmid, consisting of a response 
element (RE), a promoter gene, and the Lac-Z gene - which codes for the 
enzyme ß-galactosidase. The hER and hAR are expressed in a form capable of 
binding to the RE (ARE or ERE); once activated by a bound ligand, the 
expression of Lac-Z is triggered, resulting in the production of ß-galactosidase. 
This enzyme is in a hybrid form, possessing a peptide leader sequence, 
enabling it to pass across the cell wall of the yeast into the surrounding medium, 
where it metabolises the chromogenic substance CPRG (chlorophenol-red-ß-D- 
galactopyranoside), causing a colour change from yellow to red. This colour 
change can be monitored by eye, or measured quantitatively using a 
spectrophotometer. 
Clofibric acid was tested for both oestrogenic and androgenic activities in 
the yeast oestrogen and androgen screens (Figure 2.12). It was not considered 
that clofibric acid would be oestrogenic, as Ashby et al (1997) stated that 
Clofibrate (the parent compound) was inactive as an oestrogen in the yeast 
oestrogen assay. Oestrogenic effects are also unexpected based upon the 
chemical structures of Clofibrate and clofibric acid. Kazeto et al, (2004) also 
found clofibric acid to be non-oestrogenic and non anti-oestrogenic. 
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Figure 2.12: Lack of activity of Clofibric acid in the yeast androgen screen. 
Note that whereas DHT (the standard androgen) produced the expected dose- 
response curve, clofibric acid, at all concentrations, had absolutely no effect - 
the absorbance did not rise above the negative control (ethanol - ETOH). 
In both assays clofibric acid was inactive; that is, it showed no 
oestrogenic or androgenic properties. Figure 2.12 shows an example of the 
results obtained when clofibric acid was tested in the yeast androgen screen 
when run along-side DHT. 
2.2 Molecular Techniques 
Effects of clofibric acid in the fathead minnow at the molecular level are 
investigated in Chapters 5 and 6. The routine molecular methods employed are 
described here, with more specific details provided subsequently. 
2.3.1 RNA extraction 
TRI Reagent (Sigma) is a single step liquid phase separation that results 
in the simultaneous isolation of RNA, DNA and protein. This method is an 
improvement on the previous single step method for total RNA isolation 
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reported by Chomczynski and Sacchi, 1987. The reagent is a mixture of 
guanidine thiocyanate and phenol in a mono-phase solution, which effectively 
dissolves DNA, RNA and protein upon homogenisation of the tissue sample. 
After adding chloroform and centrifuging, the mixture separates into 3 phases: 
an aqueous phase containing the RNA, the interphase containing DNA, and an 
organic phase containing proteins. Each component can then be isolated after 
separating the phases. 
TRI Reagent is very effective for isolating RNA molecules of all types 
from 0.1 to 15kb in length. The resulting RNA is intact, with little or no 
contamination from DNA or protein. The RNA can be used for Northern blots, 
mRNA isolation, RNase protection assays, cloning and polymerase chain 
reactions (PCR). 
When preparing total RNA from tissue, it is important to inhibit as quickly 
and efficiently as possible the endogenous ribonucleases which are present in 
all living cells. Tissue samples were removed from the -80°C freezer and put 
on dry ice, before being homogenised in TRI Reagent (1mV 50-100mg of tissue) 
in eppendorf tubes (Alpha labs, Hampshire) using mini homogenisers. The 
homogenates were then left at room temperature for 5 minutes to ensure 
complete dissociation of nucleoprotein complexes. 0.2ml chloroform per ml of 
TRI Reagent used was then added, and all the tubes covered tightly and 
shaken vigorously for 15 seconds. After standing for 2-15 minutes at room 
temperature, the resulting mixture was centrifuged at 12,000x g for 15 minutes 
at 4°C. This separated the mixture into 3 phases: the red organic phase 
(containing protein), the interphase (containing DNA), and a colourless upper 
aqueous phase (containing the RNA). This aqueous phase was then 
transferred to a fresh tube and 0.5ml isopropanol per ml of TRI Reagent used 
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was added. This was then mixed and allowed to stand for 5-10 minutes at room 
temperature, before centrifuging at 12,000x g for 10 minutes at 4°C. The RNA 
precipitate formed a pellet on the side and bottom of the tube. The supernatant 
was then removed and the RNA pellet washed by adding 1 ml (minimum) 75% 
ethanol per ml of TRI Reagent used and mixed by vortexing. This was then 
centrifuged at 7,500x g for 5 minutes at 4°C. The RNA pellet was subsequently 
air-dried for approximately 10 minutes and dissolved in an appropriate amount 
of double autoclaved, sterile deionised water, by flicking the tube until 
dissolution occurred. 
2.3.1.1 Quantification of RNA 
RNA is quantified by measuring its absorbance in a spectrophotometer; 
the optical density (OD) is measured at its maximum absorbance wavelength of 
260nm. One OD unit is equivalent to 40pg/ml of RNA. Contamination of RNA 
preparations with substantial amounts of protein is demonstrated by measuring 
the OD at a wavelength of 280nm, because proteins have a maximum 
absorbance at this wavelength. A 260/280 absorbance ratio of 1.8-2.0 is 
indicative of pure RNA. 
All RNA samples were quantified by 260/280nm spectrophotometry 
(Genequant, Pharmacia, Cambridge, UK) and their integrity checked visually by 
agarose gel electrophoresis (see Section 2.3.1.3). Samples were then stored at 
-80°C until required. Samples were heated to 55-60°C just before dilution for 
assay, to ensure that the RNA was fully in solution. 
2.3.1.2 DNase treatment 
When carrying out RNA extraction, there is no guarantee that there is 
complete removal of DNA. DNAse I digests single and double stranded DNA - 
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so predigesting RNA with this enzyme eliminates any contaminating DNA prior 
to hybridisation or RT-PCR amplification. This was only carried out in 
preliminary studies (Section 5.2.2.1), because the results showed that it was not 
necessary for the analyses conducted in my project. 
2.3.1.3 Gel electrophoresis using 1.2% Agarose gels 
1.2g of agarose (BioRad, Hemel Hempstead, UK) was added to 100ml of 
lx TBE buffer (90mM Tris-borate (Amresco), 2mM EDTA (pH 8.0) (Amresco)) 
and heated in a microwave until it had completely melted. After cooling to 60°C, 
5p1 of ethidium bromide (Sigma; final concentration 0.5pg/ml) was added to the 
agarose and the flask swirled to mix the contents. The gel was then poured into 
the assembled slide, and after cooling the comb was removed and the gel 
placed into the electrophoresis apparatus (BioRad, Hemel Hempstead, UK). 
Before running, 4NI loading buffer (20% Ficoll 400 (Sigma), 1% SIDS 
(Amresco), 1mM EDTA (pH8.0), and 0.25% bromophenol blue (BDH, Poole, 
UK), 0.25% xylene cyanol (Sigma) was added to each sample, which were then 
loaded into the wells. The gel was then run in a gel tank at 78V for 1% hours. It 
was then visualised using the Alpha Imager 1220 Doc and analysis system 
V5.5. 
2.3.2 Hybridisation Protection Assays 
These kits are quantitative hybridisation assays which can measure 
specific fathead minnow mRNAs. They were kindly supplied by Molecular Light 
Techniques, Cardiff. An oligonucleotide probe, labelled with a chemiluminescent 
acridinium ester, was introduced into a sample of extracted RNA, where it 
hybridised with any of the complementary target present. The hybridisation is 
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followed by a selection step, in which label attached to free probe is hydrolysed 
to a nonchemiluminescent derivative, while label attached to hybridised probe is 
protected from such hydrolysis. After the selection step, the 
chemiluminescence is measured over a5 second interval using a luminometer 
(MLT Smartlight Luminometer). The light intensity is proportional to the 
concentration of the specific mRNA in the sample. 
RNA resuspended in nuclease-free water, which had been previously 
prepared by TRI Reagent (described above) and stored at -80°C until needed, 
was used in the assays. The concentration was 0.01,0.001/0. lug/pI dependant 
on sex (to ensure samples fitted onto the standard curve). Samples were set 
up in duplicate, as shown in Figure 2.13, in 75x12mm assay tubes, using 
nuclease-free water and RNase-free conditions throughout. 
Calibrator 
1 
Calibrator 
2 
Calibrator 
3 
Calibrator 
4 
Test 
sample 
RNA sample - - - - 50p1 Kit calibrator 50pi 50pl 50pl 50pl - Reconstituted 5Opl 50NI 50pl 50NI 50pl 
probe 
Final volume 1 00NI 1 00NI 1 00pI 1 00ul 100ul 
Table 2.1: Reaction mixtures for HPA assays. 
Four calibrators and three internal standards (synthetic target 
oligonucleotide) were also integrated (with the calibrators first, the standards at 
the beginning, middle and end of the samples) into each assay. 50p1 of sample 
RNA (or calibrator or standard) were added to the tubes, followed by 50pl of 
probe (synthetic oligonucleotide labelled with acridinium ester). The tubes were 
then covered with laboratory tape, agitated, and incubated in a water bath at 
60°C for 30min. The samples were again agitated, 300pl selection reagent 
(detergent solution) added to each tube and these were again agitated, before 
placing the tubes once more in the water bath at 60°C for 15 minutes. The 
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tubes were then taken out of the water bath and put straight on ice/water slurry 
for 2 minutes, and then at room temperature for a further 2 minutes before 
measuring the chemiluminescence associated with each tube, in order, on a 
luminometer (MLT Smartlight Luminometer) using two detection reagents (1: 
0.032 M Hydrogen peroxide, 0.001 M Nitric acid and, 2: 1.575 M Sodium 
hydroxide). 
The concentration of mRNA (both ZP3 and VTG) for each sample was 
then determined using a luminometer to measure the chemiluminescence 
associated with each sample. The light intensity is proportional to the 
concentration of mRNA in the samples. 
The Calibration Curve 
With each assay, a calibration curve was included to determine the 
concentration of mRNA in each sample (Figure 2.13). The light intensity (RLU) 
is proportional to the concentration of mRNA. 
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Figure 2.13: An example of atypical calibration curve obtained using a hybridisation protection assay. The concentration of the required mRNA in the 'unknown' sample can be extrapolated from reading the relative light units (RLU) on the y-axis and the calibrator concentration on the x-axis. 
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2.3.3 Polymerase Chain Reaction 
In the 1980's, the Polymerase Chain Reaction (PCR) was invented (Saiki 
et a/ 1985). It is an enzymatic method for making multiple copies of a selected 
segment of DNA. The process employs synthetic oligonucleotide primers, a 
themiostable DNA polymerase (such as Taq polymerase) and four 
deoxyribonucleoside triphosphates acting on the template DNA. When this is 
denatured and cooled, the primers anneal to their targets on the single stranded 
templates. The DNA polymerase then extends the primers at the 3' ends. As 
the 3' ends of the primers point towards each other, the repeated cycles of 
heating and cooling leads to a chain reaction - an exponential synthesis of 
copies of the specific segment bound by the two primers. 
PCR uses DNA, not RNA, as template - when amplifying using RNA as 
starting material, it has to be first converted into DNA (complementary or 
cDNA). This is done using a retroviral enzyme called reverse transcriptase 
(RT). This transcribes cDNA from mRNA using either a oligo-(dT) or random 
hexamer primers. The cDNA produced is then used as a template in the PCR 
reaction. Both steps together are referred to as RT-PCR. 
2.3.4 Quantitative Real time RT-PCR 
Quantitative RT-PCR was used to determine levels of expression of 
selected genes from the fathead minnow after 3 weeks exposure to clofibric 
acid (see Chapter 6 for specific method). 
PCR-based techniques allow us to obtain genetic information through 
the specific amplification of nucleic acid sequences, starting from a very low 
number of target copies. These reactions are characterised by a logarithmic 
amplification of the target sequences; that is, an increase of PCR copies 
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followed by a plateau phase showing a rapid decrease to zero of copy number 
increment per cycle. The concept of 'real time' PCR consists of the detection of 
these PCR products as they accumulate by using either labelled probes of 
primers or a fluorescent DNA dye such as Syber Green. Detection of PCR 
products in real-time allows the extrapolation of initial target concentration to be 
calculated; that is, it is a quantification method. 
The full details of primer design and construction, and the methods 
adopted for real-time PCR, are described in Chapter 6. Primers were optimised 
by performing PCR on a gradient block thermocycler to determine optimal 
annealing temperature ranges for each primer pair (data not shown). The 
following give examples of the type of results obtained when carrying out real 
time RT-PCR. 
22 
21 
20 
o19 
18 
17 
16 
------------------------------------------- --- ------------------------ 
-------------ý--- ---------------------------- 
Rß. 93 
____ RýU. 998462 - 
------------ý-------------- ---------"------ Eificien99cya1.08 ------ 
----------- 'r ----------------------------- -. ------------------------- 
-----------. ------------------------- -------------------------------- 
-------------L ------------------------------------------- 
IO OO 
Concentration 
I OOI 
Figure 2.14: An example of a standard curve used for real time RT-PCR- 
using a dilution of sample 100 (used as a standard) for relative 
quantification of the expression of certain genes. 
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dF/dT 
Figure 2.15: An example of a melt curve produced using the Rotorgene 
(see Chapter 6). The main peaks (red - standards, blue/green - samples) result 
from the specific amplification products; other peak results from formation of 
primer-dimers (seen in NTC (non-template controls) - black), which melt at a 
lower temperature. 
Fluorescence 
Figure 2.16: An example of some raw data showing an increase in 
fluorescence (and hence PCR product) with each cycle (using a serial 
dilution of sample 100 as template). 
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Figure 2.17: Amplification plot (Ct curves): each curve shows change in 
fluorescence over each cycle. These curves obtained from a serial dilution of 
sample 100 as template, used to construct a standard curve (Figure 2.14). 
Threshold set automatically to give best standard curve. 
2.4 Other analyses 
2.4.1 Water analysis 
Water samples from representative samples from some of the 
experiments (see Chapter 5) were collected from treated tanks and kindly 
analysed by Dr Malcolm Hetheridge (Brixham Environmental Laboratory, 
Devon) using a LC-MS based protocol developed in house for measurement of 
the actual concentration of clofibric acid in water samples. Calibration 
standards and samples of clofibric acid were prepared as 50: 50 
methanol: water. 
The LC separation was achieved using a 150 x 4.6 mm Genesis AQ 
column. The mobile phase used was 70% 0-01M ammonium acetate: 30% 
methanol at a flow rate of 0.7 ml min-' and an injection volume of 50 µl. The 
TSQ-700 mass spectrometer with electrospray ionisation interface (Thermo) 
was operated in negative ionisation mode, using a capillary temperature of 
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245°C, spray voltage of 4 kV, with nitrogen sheath gas of 65 psi and auxiliary 
gas of 10 ml min-'. The mass spectrometer was scanned over the mass range 
210-220 at 1 scan S"1 to monitor the [M-H] molecular ion for clofibric acid. The 
results of this analysis can be seen in Chapter 5. 
2.4.2 Statistics 
All statistical analyses were carried out using SigmaStat v2.03 (SPSS) - 
for details of specific test, see individual chapters. Differences between control 
and dosed experimental groups were analysed. In cases of normality, 
differences were determined by a t-test. A t-test is a parametric statistical test 
used to determine if there is a difference between two groups that is greater 
than what can be attributed to random sampling variation. It is based on 
estimates of the mean and standard deviation parameters of the normally 
distributed populations from which the samples were drawn. 
Where normality was not met, data were analysed using a suitable non- 
parametric test. The Mann-Whitney Rank Sum Test is used to test for a 
difference between two groups that is greater than what can be attributed to 
random sampling variation. The null hypothesis is that the two samples were 
not drawn from populations with different medians. It is a nonparametric 
procedure, which does not require normality or equal variance. It ranks all the 
observations from smallest to largest without regard to which group each 
observation comes from. The ranks for each group are summed and the rank 
sums compared. If there is no difference between the two groups, the mean 
ranks should be approximately the same. If they differ by a large amount, you 
can assume that the low ranks tend to be in one group and the high ranks are in 
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the other, and conclude that the samples were drawn from different populations 
(i. e., that there is a statistically significant difference). 
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